alpha-D-glucan - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	alpha-D-glucan	go back to main search page
Accession:	CHEBI:22385	browse the term
Synonyms:	related_synonym:	alpha-D-glucans
	alt_id:	CHEBI:10241

show annotations for term's descendants Sort by:
Rat (1650) Mouse (1900) Human (1660) Chinchilla (0) Bonobo (0) Dog (0) Squirrel (0) Pig (5) Green Monkey (0) Naked Mole-rat (0) All
Genes (1650)

dextran

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

interleukin 10

multiple interactions

[Dextrans co-treated with ferrite analog] results in increased expression of IL10 mRNA

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin-1 receptor-associated kinase 1

multiple interactions

[Dextrans co-treated with ferrite analog] results in decreased expression of IRAK1 mRNA

NCBI chr X:151,768,621...151,778,521
Ensembl chr X:151,768,777...151,778,521

G

myeloperoxidase

multiple interactions

[Probenecid binds to Dextrans] inhibits the reaction [Dextran Sulfate results in increased secretion of MPO protein]

NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819

G

solute carrier family 31 member 2

decreases uptake

SLC31A2 protein results in decreased uptake of Dextrans

NCBI chr 5:75,738,008...75,748,542
Ensembl chr 5:75,738,024...75,748,542

G

TNF receptor superfamily member 1B

multiple interactions

[Dextrans co-treated with ferrite analog] results in decreased expression of TNFRSF1B mRNA

NCBI chr 5:157,070,642...157,104,216
Ensembl chr 5:157,070,642...157,104,206

dextran sulfate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

4-aminobutyrate aminotransferase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABAT mRNA

NCBI chr10:6,996,688...7,092,835
Ensembl chr10:6,999,819...7,092,835

G

ATP binding cassette subfamily A member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ABCA1 mRNA

NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170

G

ATP binding cassette subfamily B member 11

decreases expression

Dextran Sulfate results in decreased expression of ABCB11 mRNA; Dextran Sulfate results in decreased expression of ABCB11 protein

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

ATP binding cassette subfamily B member 1A

multiple interactions
decreases expression
increases response to substance

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCB1A mRNA; ABCB1A protein affects the susceptibility to [Dextran Sulfate co-treated with 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine]
Dextran Sulfate results in decreased expression of ABCB1A mRNA
ABCB1A gene mutant form results in increased susceptibility to Dextran Sulfate

PMID:29950665 PMID:30102254 PMID:30701287 PMID:35093514

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

ATP-binding cassette, sub-family B member 1B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCB1B mRNA; ABCB1B protein affects the susceptibility to [Dextran Sulfate co-treated with 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine]

PMID:29950665 PMID:30701287

NCBI chr 4:25,242,761...25,325,194
Ensembl chr 4:25,242,798...25,325,199

G

ATP binding cassette subfamily B member 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCB4 mRNA

NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202

G

ATP binding cassette subfamily B member 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCB6 mRNA

NCBI chr 9:76,668,554...76,677,263
Ensembl chr 9:76,668,554...76,676,924

G

ATP binding cassette subfamily C member 10

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCC10 mRNA

NCBI chr 9:14,657,242...14,677,178
Ensembl chr 9:14,657,264...14,677,178

G

ATP binding cassette subfamily C member 2

decreases expression
affects response to substance
multiple interactions

Dextran Sulfate results in decreased expression of ABCC2 mRNA; Dextran Sulfate results in decreased expression of ABCC2 protein
ABCC2 protein affects the susceptibility to Dextran Sulfate
ABCC2 protein affects the susceptibility to [Dextran Sulfate co-treated with 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine]

PMID:27580383 PMID:30701287

NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238

G

ATP binding cassette subfamily C member 3

decreases expression
affects response to substance
multiple interactions

Dextran Sulfate results in decreased expression of ABCC3 mRNA; Dextran Sulfate results in decreased expression of ABCC3 protein
ABCC3 protein affects the susceptibility to Dextran Sulfate
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCC3 mRNA; ABCC3 protein affects the susceptibility to [Dextran Sulfate co-treated with 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine]

PMID:27580383 PMID:29950665 PMID:30701287

NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595

G

ATP binding cassette subfamily C member 4

multiple interactions
decreases expression

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of ABCC4 mRNA; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ABCC4 mRNA
Dextran Sulfate results in decreased expression of ABCC4 mRNA; Dextran Sulfate results in decreased expression of ABCC4 protein

PMID:26271895 PMID:27580383 PMID:29950665

NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283

G

ATP binding cassette subfamily C member 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCC5 mRNA

NCBI chr11:80,473,809...80,567,257
Ensembl chr11:80,473,872...80,567,253

G

ATP binding cassette subfamily C member 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCC6 mRNA

NCBI chr 1:96,447,224...96,501,464
Ensembl chr 1:96,447,251...96,501,464

G

ATP binding cassette subfamily C member 9

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ABCC9 mRNA

NCBI chr 4:175,531,854...175,655,849
Ensembl chr 4:175,532,547...175,655,356

G

ATP binding cassette subfamily F member 2

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of ABCF2 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of ABCF2 protein]

NCBI chr 4:10,594,802...10,607,620
Ensembl chr 4:10,594,907...10,607,606

G

ATP binding cassette subfamily G member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ABCG1 mRNA

NCBI chr20:9,126,687...9,182,948
Ensembl chr20:9,126,687...9,182,948

G

ATP binding cassette subfamily G member 2

multiple interactions
decreases expression
affects response to substance

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCG2 mRNA; ABCG2 protein affects the susceptibility to [Dextran Sulfate co-treated with 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine]
Rifampin promotes the reaction [Dextran Sulfate results in decreased expression of ABCG2 mRNA]
Dextran Sulfate results in decreased expression of ABCG2 mRNA; Dextran Sulfate results in decreased expression of ABCG2 protein
ABCG2 protein affects the susceptibility to Dextran Sulfate

PMID:29950665 PMID:30701287 PMID:38423481

NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409

G

abl-interactor 1

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of ABI1 protein]

NCBI chr17:85,098,837...85,179,829
Ensembl chr17:85,098,550...85,179,792

G

acetyl-CoA acyltransferase 1A

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACAA1A mRNA

NCBI chr 8:119,079,401...119,088,626
Ensembl chr 8:119,079,775...119,088,624

G

acetyl-Coenzyme A acyltransferase 1B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACAA1B mRNA

NCBI chr 8:118,872,996...118,881,852
Ensembl chr 8:118,872,997...118,881,825

G

acetyl-CoA acyltransferase 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACAA2 mRNA

NCBI chr18:68,345,136...68,373,246
Ensembl chr18:68,345,012...68,373,249

G

acetyl-CoA carboxylase alpha

multiple interactions
increases expression

Erianin inhibits the reaction [Dextran Sulfate results in increased expression of ACACA protein]

NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457

G

acyl-CoA dehydrogenase short chain

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACADS mRNA

NCBI chr12:41,493,650...41,502,897
Ensembl chr12:41,493,626...41,502,898

G

acyl-CoA dehydrogenase, short/branched chain

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACADSB mRNA

NCBI chr 1:186,188,939...186,227,796
Ensembl chr 1:186,188,987...186,230,379

G

angiotensin I converting enzyme

multiple interactions
increases abundance

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACE mRNA
dextran sodium sulfate increases abundance of Ace protein in small and large intestine extracellular space

CTD
RGD

PMID:29950665 PMID:26401072

NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131

G

acetylcholinesterase

multiple interactions
decreases activity

[Chlorpyrifos co-treated with Dextran Sulfate] results in decreased activity of ACHE protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACHE mRNA
Dextran Sulfate results in decreased activity of ACHE protein

PMID:29950665 PMID:31226429 PMID:31807802

NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651

G

atypical chemokine receptor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACKR1 mRNA

NCBI chr13:85,782,396...85,784,015
Ensembl chr13:85,782,398...85,783,983

G

atypical chemokine receptor 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACKR2 mRNA

NCBI chr 8:121,559,563...121,573,633
Ensembl chr 8:121,561,211...121,573,582

G

atypical chemokine receptor 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACKR3 mRNA

NCBI chr 9:90,799,682...90,811,246
Ensembl chr 9:90,799,686...90,811,237

G

atypical chemokine receptor 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACKR4 mRNA

NCBI chr 8:104,716,537...104,720,972
Ensembl chr 8:104,716,067...104,723,617

G

acyl-CoA synthetase bubblegum family member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACSBG2 mRNA

NCBI chr 9:1,683,846...1,715,517
Ensembl chr 9:1,683,847...1,714,518

G

acyl-CoA synthetase medium-chain family member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACSM1 mRNA

NCBI chr 1:173,985,715...174,020,565
Ensembl chr 1:173,984,672...174,025,495

G

acyl-CoA synthetase medium-chain family member 3

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of ACSM3 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of ACSM3 protein]

NCBI chr 1:174,133,260...174,159,966
Ensembl chr 1:174,133,288...174,160,184

G

acyl-CoA synthetase short-chain family member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACSS1 mRNA

NCBI chr 3:139,450,383...139,500,325
Ensembl chr 3:139,450,383...139,500,325

G

acyl-CoA synthetase short-chain family member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACSS2 mRNA

NCBI chr 3:144,003,808...144,047,452
Ensembl chr 3:144,004,336...144,059,675

G

actin-like 6A

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of ACTL6A protein]

NCBI chr 2:115,492,374...115,508,401
Ensembl chr 2:115,492,285...115,508,401

G

actinin, alpha 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACTN1 mRNA

NCBI chr 6:98,998,553...99,093,334
Ensembl chr 6:98,998,556...99,093,251

G

actinin alpha 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACTN2 mRNA

NCBI chr17:58,143,334...58,210,622
Ensembl chr17:58,142,625...58,210,622

G

actin related protein 2

decreases expression

Dextran Sulfate results in decreased expression of ACTR2 protein

NCBI chr14:94,296,443...94,333,735
Ensembl chr14:94,296,443...94,340,524

G

actin related protein 3

decreases expression

Dextran Sulfate results in decreased expression of ACTR3 protein

NCBI chr13:36,800,739...36,843,837
Ensembl chr13:36,800,093...36,844,124

G

activin A receptor type 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACVR1 mRNA

NCBI chr 3:42,978,558...43,097,892
Ensembl chr 3:42,978,561...43,098,241

G

aminoacylase 1

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of ACY1 protein

NCBI chr 8:107,072,354...107,077,756
Ensembl chr 8:107,072,358...107,077,682

G

adenosine deaminase

increases expression
multiple interactions

Dextran Sulfate results in increased expression of ADA protein
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of ADA protein]

NCBI chr 3:152,398,745...152,422,854
Ensembl chr 3:152,398,747...152,447,088

G

ADAM metallopeptidase domain 17

multiple interactions
increases expression
affects response to substance

ADAM17 protein affects the reaction [Dextran Sulfate results in decreased expression of SIRT1 mRNA]; ADAM17 protein affects the reaction [Dextran Sulfate results in decreased expression of TIMP3 mRNA]; ADAM17 protein affects the reaction [Dextran Sulfate results in increased expression of IFNG protein]; ADAM17 protein affects the reaction [Dextran Sulfate results in increased expression of IL17A protein]; ADAM17 protein affects the reaction [Dextran Sulfate results in increased expression of IL1B protein]; ADAM17 protein affects the reaction [Dextran Sulfate results in increased expression of IL6 protein]; ADAM17 protein affects the reaction [Dextran Sulfate results in increased expression of TNF protein]; resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of ADAM17 mRNA]
ADAM17 protein affects the susceptibility to Dextran Sulfate

NCBI chr 6:40,872,936...40,920,700
Ensembl chr 6:40,872,856...40,920,639

G

ADAM metallopeptidase with thrombospondin type 1 motif, 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADAMTS1 mRNA

NCBI chr11:24,932,227...24,941,068
Ensembl chr11:24,931,761...24,941,103

G

ADAM metallopeptidase with thrombospondin type 1 motif, 14

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADAMTS14 mRNA

NCBI chr20:29,143,029...29,219,846
Ensembl chr20:29,144,354...29,219,866

G

ADAM metallopeptidase with thrombospondin type 1 motif, 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADAMTS2 mRNA

NCBI chr10:34,920,992...35,126,465
Ensembl chr10:34,921,049...35,123,821

G

ADAM metallopeptidase with thrombospondin type 1 motif, 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADAMTS4 mRNA

NCBI chr13:83,670,556...83,680,045
Ensembl chr13:83,670,183...83,680,065

G

ADAM metallopeptidase with thrombospondin type 1 motif, 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADAMTS5 mRNA

NCBI chr11:25,000,627...25,047,205
Ensembl chr11:25,000,637...25,047,205

G

adenylate cyclase 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADCY2 mRNA

NCBI chr 1:34,375,639...34,822,252
Ensembl chr 1:34,375,895...34,822,236

G

adenylate cyclase 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADCY4 mRNA

NCBI chr15:29,266,280...29,282,153
Ensembl chr15:29,266,287...29,282,108

G

adenylate cyclase 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ADCY6 mRNA

NCBI chr 7:129,742,827...129,763,922
Ensembl chr 7:129,742,838...129,763,754

G

adenylate cyclase 7

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADCY7 mRNA
Dextran Sulfate results in decreased expression of ADCY7 mRNA

PMID:29950665 PMID:35093514

NCBI chr19:18,740,875...18,798,924
Ensembl chr19:18,740,875...18,776,311

G

adenylate cyclase activating polypeptide 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADCYAP1 mRNA

NCBI chr 9:113,102,632...113,122,500
Ensembl chr 9:113,103,718...113,109,773

G

ADCYAP receptor type I

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ADCYAP1R1 mRNA

NCBI chr 4:84,593,558...84,642,700
Ensembl chr 4:84,593,892...84,642,700

G

adhesion G protein-coupled receptor A2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADGRA2 mRNA

NCBI chr16:64,932,964...64,971,433
Ensembl chr16:64,933,315...64,971,483

G

adhesion G protein-coupled receptor B1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ADGRB1 mRNA

NCBI chr 7:106,404,827...106,476,902
Ensembl chr 7:106,404,958...106,476,902

G

adhesion G protein-coupled receptor E1

increases expression
multiple interactions

Dextran Sulfate results in increased expression of ADGRE1 protein
flavokawain B inhibits the reaction [Dextran Sulfate results in increased expression of ADGRE1 protein]

NCBI chr 9:2,242,476...2,398,000
Ensembl chr 9:2,242,474...2,398,000

G

adhesion G protein-coupled receptor E5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADGRE5 mRNA

NCBI chr19:24,397,972...24,418,648
Ensembl chr19:24,398,689...24,418,638

G

adhesion G protein-coupled receptor F1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADGRF1 mRNA

NCBI chr 9:17,661,258...17,696,359
Ensembl chr 9:17,660,930...17,711,704

G

adhesion G protein-coupled receptor F5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADGRF5 mRNA

NCBI chr 9:17,517,596...17,624,107
Ensembl chr 9:17,520,009...17,623,968

G

alcohol dehydrogenase 1C (class I), gamma polypeptide

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADH1 mRNA

NCBI chr 2:226,797,303...226,808,892
Ensembl chr 2:226,797,303...226,808,892

G

alcohol dehydrogenase 5 (class III), chi polypeptide

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ADH5 mRNA

NCBI chr 2:226,975,184...226,987,591
Ensembl chr 2:226,947,466...226,987,591

G

adrenomedullin

multiple interactions
increases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADM mRNA
Dextran Sulfate results in increased expression of ADM mRNA

PMID:29950665 PMID:35093514

NCBI chr 1:164,745,484...164,747,655
Ensembl chr 1:164,745,466...164,747,654

G

adenosine A2a receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADORA2A mRNA

NCBI chr20:13,315,848...13,333,386
Ensembl chr20:13,315,853...13,333,386

G

adenosine A2B receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of ADORA2B mRNA

NCBI chr10:46,940,394...46,956,772
Ensembl chr10:46,940,384...46,956,772

G

adenosine A3 receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADORA3 mRNA

NCBI chr 2:193,352,759...193,392,946
Ensembl chr 2:193,388,713...193,392,357

G

adrenoceptor alpha 2A

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ADRA2A mRNA

NCBI chr 1:253,061,480...253,064,280
Ensembl chr 1:253,060,218...253,064,365

G

adrenoceptor beta 2

multiple interactions

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of ADRB2 mRNA; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADRB2 mRNA

PMID:26271895 PMID:29950665

NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512

G

angiotensinogen

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AGT mRNA
Dextran Sulfate results in decreased expression of AGT mRNA

PMID:29950665 PMID:35093514

NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977

G

AHNAK nucleoprotein

decreases expression

Dextran Sulfate results in decreased expression of AHNAK mRNA

NCBI chr 1:205,882,225...205,970,934
Ensembl chr 1:205,882,273...205,970,926

G

aryl hydrocarbon receptor

multiple interactions
increases response to substance

AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of CXCL1 mRNA]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of CXCL2 mRNA]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of IL17A mRNA]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of IL1B mRNA]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of LCN2 mRNA]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of PTGS2 mRNA]
AHR gene mutant form results in increased susceptibility to Dextran Sulfate

NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568

G

alpha hemoglobin stabilizing protein

decreases expression

Dextran Sulfate results in decreased expression of AHSP protein

NCBI chr 1:182,879,901...182,885,508
Ensembl chr 1:182,880,076...182,885,506

G

adenylate kinase 1

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of AK1 protein
[Dextran Sulfate co-treated with bisphenol A] results in increased expression of AK1 protein

NCBI chr 3:15,912,431...15,923,045
Ensembl chr 3:15,912,485...15,923,041

G

A-kinase anchoring protein 12

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AKAP12 mRNA

NCBI chr 1:40,730,123...40,819,863
Ensembl chr 1:40,730,123...40,819,886

G

A-kinase anchoring protein 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AKAP5 mRNA

NCBI chr 6:95,051,527...95,061,075
Ensembl chr 6:95,051,537...95,061,578

G

aldo-keto reductase family 1 member B1

decreases expression
increases expression
multiple interactions

Dextran Sulfate results in decreased expression of AKR1B1 protein
Dextran Sulfate results in increased expression of AKR1B1 mRNA
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AKR1B1 mRNA

PMID:29950665 PMID:35093514 PMID:35999755

NCBI chr 4:62,932,033...62,946,126
Ensembl chr 4:62,932,031...62,946,157

G

aldo-keto reductase family 1, member C3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of AKR1C18 mRNA

NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873

G

AKT serine/threonine kinase 1

multiple interactions

[APC protein affects the susceptibility to Dextran Sulfate] which results in increased phosphorylation of AKT1 protein; resorcinol inhibits the reaction [[APC protein affects the susceptibility to Dextran Sulfate] which results in increased phosphorylation of AKT1 protein]
banxia xiexin decoction inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased phosphorylation of AKT1 protein]; Dextran Sulfate results in increased expression of and results in increased phosphorylation of AKT1 protein; palmatine inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased phosphorylation of AKT1 protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased phosphorylation of AKT1 protein]

PMID:26262998 PMID:36806191

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

albumin

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of ALB protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ALB mRNA

PMID:29950665 PMID:35999755

NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836

G

aldehyde dehydrogenase 1 family, member A1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ALDH1A1 mRNA

NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961

G

aldehyde dehydrogenase 1 family, member B1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ALDH1B1 mRNA

NCBI chr 5:60,063,370...60,068,378
Ensembl chr 5:60,063,225...60,068,378

G

aldehyde dehydrogenase 2 family member

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ALDH2 mRNA

NCBI chr12:34,949,549...34,982,527
Ensembl chr12:34,901,219...34,982,521

G

aldehyde dehydrogenase 3 family, member A2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ALDH3A2 mRNA

NCBI chr10:45,928,313...45,949,366
Ensembl chr10:45,908,524...45,949,281

G

aldehyde dehydrogenase 7 family, member A1

multiple interactions
increases expression

Erianin inhibits the reaction [Dextran Sulfate results in increased expression of ALDH7A1 protein]

NCBI chr18:50,003,242...50,042,193
Ensembl chr18:50,009,934...50,042,193

G

aldolase, fructose-bisphosphate C

decreases expression

Dextran Sulfate results in decreased expression of ALDOA protein; Dextran Sulfate results in decreased expression of ALDOC mRNA

PMID:35093514 PMID:35999755

NCBI chr10:63,217,477...63,221,066
Ensembl chr10:63,217,451...63,221,066

G

arachidonate 12-lipoxygenase, 12S type

decreases expression

Dextran Sulfate results in decreased expression of ALOX12 protein

NCBI chr10:54,958,263...54,970,542
Ensembl chr10:54,958,271...54,970,542

G

arachidonate 12-lipoxygenase, 12R type

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ALOX12B mRNA

NCBI chr10:53,863,060...53,874,938
Ensembl chr10:53,863,060...53,874,938

G

arachidonate 5-lipoxygenase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ALOX5 mRNA

NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743

G

arachidonate 5-lipoxygenase activating protein

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ALOX5AP mRNA

NCBI chr12:5,748,941...5,772,986
Ensembl chr12:5,748,944...5,772,986

G

alkaline phosphatase, biomineralization associated

multiple interactions
increases activity

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ALPL mRNA
Dextran Sulfate results in increased activity of ALPL protein

PMID:29950665 PMID:30489199

NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446

G

angiopoietin 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ANGPT4 mRNA

NCBI chr 3:140,420,389...140,454,213
Ensembl chr 3:140,420,389...140,453,583

G

angiopoietin-like 4

increases expression

Dextran Sulfate results in increased expression of ANGPTL4 mRNA

NCBI chr 7:14,550,288...14,557,797
Ensembl chr 7:14,550,311...14,556,519

G

anoctamin 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ANO1 mRNA

NCBI chr 1:199,751,439...199,900,099
Ensembl chr 1:199,751,439...199,900,069

G

anoctamin 10

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ANO10 mRNA

NCBI chr 8:121,841,664...121,960,739
Ensembl chr 8:121,841,665...121,962,670

G

anoctamin 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ANO6 mRNA

NCBI chr 7:126,933,919...127,113,588
Ensembl chr 7:126,933,936...127,113,589

G

anoctamin 7

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ANO7 mRNA

NCBI chr 9:93,917,524...93,945,323
Ensembl chr 9:93,917,524...93,945,323

G

anoctamin 9

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ANO9 mRNA

NCBI chr 1:196,208,863...196,230,381
Ensembl chr 1:196,197,341...196,229,900

G

annexin A1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ANXA1 mRNA

NCBI chr 1:217,861,175...217,877,205
Ensembl chr 1:217,861,175...217,877,343

G

annexin A4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ANXA4 mRNA

NCBI chr 4:119,184,378...119,241,183
Ensembl chr 4:119,184,374...119,241,161

G

adaptor related protein complex 1 subunit mu 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AP1M1 mRNA

NCBI chr16:17,586,886...17,602,410
Ensembl chr16:17,584,730...17,602,403

G

adaptor related protein complex 1 subunit sigma 1

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of AP1S1 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of AP1S1 protein]

NCBI chr12:19,625,267...19,635,792
Ensembl chr12:19,625,332...19,756,713

G

APC regulator of WNT signaling pathway

affects response to substance
multiple interactions

APC affects the susceptibility to Dextran Sulfate; APC protein affects the susceptibility to Dextran Sulfate
[APC protein affects the susceptibility to Dextran Sulfate] which affects the activity of MPO protein; [APC protein affects the susceptibility to Dextran Sulfate] which results in increased chemical synthesis of PTEN protein modified form; [APC protein affects the susceptibility to Dextran Sulfate] which results in increased phosphorylation of AKT1 protein; PDE4B protein affects the reaction [APC protein affects the susceptibility to Dextran Sulfate]; resorcinol inhibits the reaction [[APC protein affects the susceptibility to Dextran Sulfate] which affects the activity of MPO protein]; resorcinol inhibits the reaction [[APC protein affects the susceptibility to Dextran Sulfate] which results in increased chemical synthesis of PTEN protein modified form]; resorcinol inhibits the reaction [[APC protein affects the susceptibility to Dextran Sulfate] which results in increased phosphorylation of AKT1 protein]

PMID:16049979 PMID:26262998 PMID:30188895

NCBI chr18:25,828,558...25,925,511
Ensembl chr18:25,864,222...25,922,696

G

amyloid P component, serum

increases expression

Dextran Sulfate results in increased expression of APCS protein

NCBI chr13:85,373,219...85,374,195
Ensembl chr13:85,373,220...85,374,298

G

apelin

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of APLN mRNA
Dextran Sulfate results in decreased expression of APLN mRNA

PMID:29950665 PMID:35093514

NCBI chr X:127,180,801...127,213,567
Ensembl chr X:127,203,823...127,213,391

G

apolipoprotein A2

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of APOA2 protein

NCBI chr13:83,644,460...83,646,358
Ensembl chr13:83,644,470...83,646,355

G

apolipoprotein A4

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of APOA4 protein
[Dextran Sulfate co-treated with bisphenol A] results in increased expression of APOA4 protein; Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of APOA4 protein]

PMID:32272095 PMID:35999755

NCBI chr 8:46,539,083...46,541,464
Ensembl chr 8:46,539,082...46,541,469

G

apolipoprotein B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of APOB mRNA

NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497

G

apolipoprotein C2

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in increased expression of APOC2 protein

NCBI chr 1:79,329,429...79,334,397
Ensembl chr 1:79,329,428...79,334,476

G

apolipoprotein E

increases expression
multiple interactions

Dextran Sulfate results in increased expression of APOE protein
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of APOE protein]

NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932

G

amyloid beta precursor protein

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of APP mRNA

NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561

G

aquaporin 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of AQP1 mRNA

NCBI chr 4:84,482,512...84,494,690
Ensembl chr 4:84,482,512...84,494,690

G

aquaporin 11

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of AQP11 mRNA

NCBI chr 1:152,046,515...152,056,675
Ensembl chr 1:152,046,517...152,056,725

G

aquaporin 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AQP2 mRNA

NCBI chr 7:130,711,433...130,716,468
Ensembl chr 7:130,711,413...130,716,468

G

aquaporin 3 (Gill blood group)

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AQP3 mRNA

NCBI chr 5:56,239,200...56,244,718
Ensembl chr 5:56,239,201...56,244,720

G

aquaporin 8

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of AQP8 mRNA

NCBI chr 1:177,993,313...177,999,158
Ensembl chr 1:177,993,305...177,999,158

G

aquaporin 9

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AQP9 mRNA

NCBI chr 8:71,797,231...71,837,485
Ensembl chr 8:71,797,234...71,837,395

G

androgen receptor

multiple interactions
increases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AR mRNA
Dextran Sulfate results in increased expression of AR mRNA

PMID:27920257 PMID:29950665

NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925

G

ADP-ribosylation factor 3

decreases expression

Dextran Sulfate results in decreased expression of ARF3 protein

NCBI chr 7:129,886,082...129,912,022
Ensembl chr 7:129,886,082...129,912,002

G

arginase 1

multiple interactions
decreases expression

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARG1 mRNA; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARG1 protein; BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of ARG1 mRNA]; BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of ARG1 protein]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of ARG1 mRNA]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of ARG1 protein]]; IRF4 protein promotes the reaction [Dextran Sulfate results in decreased expression of ARG1 mRNA]; IRF4 protein promotes the reaction [Dextran Sulfate results in decreased expression of ARG1 protein]; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARG1 mRNA]; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARG1 protein]
Dextran Sulfate results in decreased expression of ARG1 mRNA; Dextran Sulfate results in decreased expression of ARG1 protein

PMID:25026504 PMID:38164749

NCBI chr 1:20,475,878...20,488,422
Ensembl chr 1:20,475,968...20,488,422

G

Rho GTPase activating protein 1

decreases expression

Dextran Sulfate results in decreased expression of ARHGAP1 protein

NCBI chr 3:77,621,377...77,643,400
Ensembl chr 3:77,620,655...77,643,396

G

Rho GTPase activating protein 15

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ARHGAP15 mRNA

NCBI chr 3:27,989,368...28,592,722
Ensembl chr 3:27,989,633...28,600,265

G

Rho GTPase activating protein 20

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARHGAP20 mRNA

NCBI chr 8:52,074,472...52,155,739
Ensembl chr 8:52,074,158...52,155,739

G

Rho GTPase activating protein 25

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ARHGAP25 mRNA

NCBI chr 4:119,896,844...119,974,982
Ensembl chr 4:119,896,844...119,974,982

G

Rho GTPase activating protein 40

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARHGAP40 mRNA

NCBI chr 3:147,165,781...147,206,552
Ensembl chr 3:147,165,729...147,207,203

G

Rho GDP dissociation inhibitor alpha

decreases expression

Dextran Sulfate results in decreased expression of ARHGDIA protein

NCBI chr10:105,854,526...105,858,020
Ensembl chr10:105,854,533...105,858,023

G

Rho GDP dissociation inhibitor beta

increases expression
decreases expression
multiple interactions

Dextran Sulfate results in increased expression of ARHGDIB mRNA
Dextran Sulfate results in decreased expression of ARHGDIB protein
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ARHGDIB mRNA

PMID:23894361 PMID:29950665 PMID:35999755

NCBI chr 4:169,822,951...169,841,884
Ensembl chr 4:169,822,952...169,841,658

G

Rho guanine nucleotide exchange factor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ARHGEF1 mRNA

NCBI chr 1:80,499,026...80,520,954
Ensembl chr 1:80,499,131...80,520,953

G

Rho guanine nucleotide exchange factor 12

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARHGEF12 mRNA

NCBI chr 8:43,350,070...43,475,404
Ensembl chr 8:43,353,799...43,476,366

G

Rac/Cdc42 guanine nucleotide exchange factor 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ARHGEF6 mRNA

NCBI chr X:135,145,447...135,264,636
Ensembl chr X:135,146,786...135,275,304

G

ADP ribosylation factor like GTPase 3

increases expression

Dextran Sulfate results in increased expression of ARL3 mRNA

NCBI chr 1:245,400,659...245,446,673
Ensembl chr 1:245,400,550...245,446,820

G

ADP-ribosylation factor like GTPase 9

increases expression

Dextran Sulfate results in increased expression of ARL9 mRNA

NCBI chr14:31,157,573...31,166,803
Ensembl chr14:31,157,586...31,166,699

G

actin related protein 2/3 complex, subunit 2

decreases expression

Dextran Sulfate results in decreased expression of ARPC2 protein

NCBI chr 9:75,820,782...75,851,471
Ensembl chr 9:75,820,770...75,851,471

G

actin related protein 2/3 complex, subunit 3

multiple interactions
decreases expression

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of ARPC3 protein
Dextran Sulfate results in decreased expression of ARPC3 protein

NCBI chr12:34,172,780...34,186,651
Ensembl chr12:34,172,780...34,186,651

G

actin related protein 2/3 complex, subunit 4

decreases expression

Dextran Sulfate results in decreased expression of ARPC4 protein

NCBI chr 4:146,522,255...146,532,784
Ensembl chr 4:146,522,176...146,532,785

G

arrestin, beta 2

multiple interactions

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of ARRB2 mRNA

NCBI chr10:55,146,887...55,154,854
Ensembl chr10:55,146,818...55,154,850

G

arylsulfatase B

decreases expression

Dextran Sulfate results in decreased expression of ARSB mRNA

NCBI chr 2:25,002,210...25,162,675
Ensembl chr 2:25,002,346...25,162,671

G

ankyrin repeat and SOCS box-containing 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ASB2 mRNA

NCBI chr 6:122,474,754...122,511,014
Ensembl chr 6:122,474,756...122,510,854

G

acid sensing ion channel subunit family member 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ASIC4 mRNA

NCBI chr 9:76,941,532...76,962,900
Ensembl chr 9:76,941,532...76,962,900

G

argininosuccinate synthase 1

decreases expression

Dextran Sulfate results in decreased expression of ASS1 mRNA

NCBI chr 3:14,747,355...14,796,909
Ensembl chr 3:14,747,368...14,796,903

G

autophagy related 5

multiple interactions
increases expression

2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [alpinetin promotes the reaction [Dextran Sulfate results in increased expression of ATG5 mRNA]]; 6-formylindolo(3,2-b)carbazole promotes the reaction [Dextran Sulfate results in increased expression of ATG5 mRNA]; [Dietary Fats co-treated with Dextran Sulfate] results in decreased expression of ATG5 mRNA; alpinetin promotes the reaction [Dextran Sulfate results in increased expression of ATG5 mRNA]; ATG5 protein affects the reaction [HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]]; ATG5 protein affects the reaction [HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased secretion of IL1B protein]]; Leucine inhibits the reaction [alpinetin promotes the reaction [Dextran Sulfate results in increased expression of ATG5 mRNA]]; obeticholic acid inhibits the reaction [[Dietary Fats co-treated with Dextran Sulfate] results in decreased expression of ATG5 mRNA]

PMID:27611972 PMID:31676321 PMID:35439472

NCBI chr20:47,798,217...47,889,216
Ensembl chr20:47,798,290...47,889,209

G

autophagy related 7

multiple interactions
increases expression

2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [alpinetin promotes the reaction [Dextran Sulfate results in increased expression of ATG7 mRNA]]; 6-formylindolo(3,2-b)carbazole promotes the reaction [Dextran Sulfate results in increased expression of ATG7 mRNA]; alpinetin promotes the reaction [Dextran Sulfate results in increased expression of ATG7 mRNA]; Leucine inhibits the reaction [alpinetin promotes the reaction [Dextran Sulfate results in increased expression of ATG7 mRNA]]

NCBI chr 4:147,718,663...147,925,656
Ensembl chr 4:147,718,752...147,925,593

G

5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase

decreases expression

Dextran Sulfate results in decreased expression of ATIC protein

NCBI chr 9:73,164,846...73,184,897
Ensembl chr 9:73,164,846...73,184,889

G

ATPase phospholipid transporting 10A (putative)

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP10A mRNA

NCBI chr 1:109,556,760...109,730,440
Ensembl chr 1:109,556,782...109,730,437

G

ATPase phospholipid transporting 11B (putative)

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP11B mRNA

NCBI chr 2:118,585,348...118,691,076
Ensembl chr 2:118,585,342...118,690,232

G

ATPase H+/K+ transporting non-gastric alpha2 subunit

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP12A mRNA

NCBI chr15:30,443,571...30,468,229
Ensembl chr15:30,443,571...30,468,229

G

ATPase Na+/K+ transporting subunit alpha 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP1A1 mRNA

NCBI chr 2:189,020,722...189,048,826
Ensembl chr 2:189,020,722...189,048,837

G

ATPase Na+/K+ transporting subunit alpha 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP1A3 mRNA

NCBI chr 1:80,572,790...80,601,936
Ensembl chr 1:80,572,796...80,601,918

G

ATPase Na+/K+ transporting subunit alpha 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP1A4 mRNA

NCBI chr13:84,683,766...84,719,790
Ensembl chr13:84,683,768...84,719,687

G

ATPase Na+/K+ transporting subunit beta 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP1B1 mRNA

NCBI chr13:76,786,580...76,807,096
Ensembl chr13:76,786,578...76,807,459

G

ATPase Na+/K+ transporting subunit beta 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP1B3 mRNA

NCBI chr 8:96,910,265...96,941,592
Ensembl chr 8:96,910,309...96,941,598

G

ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP2A1 mRNA

NCBI chr 1:181,026,606...181,044,859
Ensembl chr 1:181,026,608...181,044,838

G

ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP2A3 mRNA

NCBI chr10:57,581,742...57,612,758
Ensembl chr10:57,582,128...57,612,748

G

ATPase plasma membrane Ca2+ transporting 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP2B1 mRNA

NCBI chr 7:33,735,595...33,845,226
Ensembl chr 7:33,735,871...33,843,295

G

ATPase secretory pathway Ca2+ transporting 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of ATP2C2 mRNA

NCBI chr19:47,754,120...47,811,369
Ensembl chr19:47,754,120...47,811,368

G

ATPase H+/K+ transporting subunit beta

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP4B mRNA

NCBI chr16:76,144,150...76,153,063
Ensembl chr16:76,144,150...76,153,063

G

ATPase H+ transporting V0 subunit a2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP6V0A2 mRNA

NCBI chr12:31,947,220...31,979,875
Ensembl chr12:31,822,733...32,007,069

G

ATPase H+ transporting V0 subunit a4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP6V0A4 mRNA

NCBI chr 4:66,760,163...66,842,126
Ensembl chr 4:66,760,159...66,842,110

G

ATPase H+ transporting V0 subunit D2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP6V0D2 mRNA

NCBI chr 5:33,336,257...33,385,354
Ensembl chr 5:33,336,264...33,385,354

G

ATPase H+ transporting V1 subunit E2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP6V1E2 mRNA

NCBI chr 6:7,667,359...7,673,711
Ensembl chr 6:7,667,564...7,672,626

G

ATPase H+ transporting V1 subunit F

increases expression

Dextran Sulfate results in increased expression of ATP6V1F mRNA

NCBI chr 4:58,067,666...58,070,628

G

ATPase H+ transporting V1 subunit G3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP6V1G3 mRNA

NCBI chr13:49,800,256...49,825,247
Ensembl chr13:49,794,222...49,825,247

G

ATPase copper transporting alpha

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP7A mRNA

NCBI chr X:71,094,144...71,201,550
Ensembl chr X:71,094,202...71,198,354

G

ATPase phospholipid transporting 8B1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP8B1 mRNA

NCBI chr18:58,016,382...58,157,213
Ensembl chr18:58,018,268...58,157,396

G

ATPase phospholipid transporting 8B2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP8B2 mRNA

NCBI chr 2:175,378,514...175,402,265
Ensembl chr 2:175,378,517...175,401,883

G

arginine vasopressin receptor 1A

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AVPR1A mRNA

NCBI chr 7:58,114,306...58,118,230
Ensembl chr 7:58,114,284...58,122,215

G

arginine vasopressin receptor 1B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AVPR1B mRNA

NCBI chr13:43,046,531...43,059,046
Ensembl chr13:43,046,267...43,057,792

G

arginine vasopressin receptor 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of AVPR2 mRNA

NCBI chr X:151,633,501...151,636,155
Ensembl chr X:151,633,522...151,635,989

G

axin 2

multiple interactions

[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of AXIN2 mRNA; [Dextran Sulfate co-treated with Azoxymethane] results in increased expression of AXIN2 protein; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of AXIN2 mRNA]; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of AXIN2 protein]

NCBI chr10:93,893,830...93,927,042
Ensembl chr10:93,899,245...93,926,231

G

UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of B3GNT3 mRNA

NCBI chr16:18,401,405...18,410,821
Ensembl chr16:18,401,405...18,410,766

G

UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 7

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of B3GNT7 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of B3GNT7 protein]

NCBI chr 9:86,956,220...86,960,171
Ensembl chr 9:86,956,220...86,960,170

G

UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 8

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of B3GNT8 mRNA

NCBI chr 1:81,135,602...81,138,501
Ensembl chr 1:81,135,499...81,142,263

G

bile acid CoA:amino acid N-acyltransferase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BAAT mRNA

NCBI chr 5:63,851,668...63,860,641
Ensembl chr 5:63,850,705...63,860,685

G

BAF nuclear assembly factor 1

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of BANF1 protein]

NCBI chr 1:202,672,170...202,674,215
Ensembl chr 1:202,671,305...202,674,188

G

B-cell scaffold protein with ankyrin repeats 1

increases expression

Dextran Sulfate results in increased expression of BANK1 mRNA

NCBI chr 2:224,530,475...224,800,420
Ensembl chr 2:224,530,475...224,800,405

G

BCL2 associated X, apoptosis regulator

multiple interactions
increases expression

[RASSF1 gene mutant form results in increased susceptibility to Dextran Sulfate] which results in increased expression of BAX mRNA; [RASSF1 gene mutant form results in increased susceptibility to Dextran Sulfate] which results in increased expression of BAX protein; daphnetin inhibits the reaction [Dextran Sulfate results in increased expression of BAX protein]; flavokawain B inhibits the reaction [Dextran Sulfate results in increased cleavage of BAX protein]; flavokawain B inhibits the reaction [Dextran Sulfate results in increased expression of BAX protein]

PMID:24146755 PMID:37209277 PMID:38583725

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

butyrylcholinesterase

multiple interactions
decreases activity

[Chlorpyrifos co-treated with Dextran Sulfate] results in decreased activity of BCHE protein
Dextran Sulfate results in decreased activity of BCHE protein

PMID:31226429 PMID:31807802

NCBI chr 2:158,308,674...158,401,148
Ensembl chr 2:158,307,584...158,401,148

G

BCL2, apoptosis regulator

multiple interactions
decreases expression

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BCL2 protein; Aspirin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BCL2 protein]; Camptothecin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BCL2 protein]; daphnetin inhibits the reaction [Dextran Sulfate results in decreased expression of BCL2 protein]; flavokawain B inhibits the reaction [Dextran Sulfate results in decreased expression of BCL2 protein]; Plant Extracts inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BCL2 protein]

PMID:25449198 PMID:37209277 PMID:38583725

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

BCL6, transcription repressor

multiple interactions

BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of and results in decreased secretion of IL10 protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of ARG1 mRNA]; BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of ARG1 protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of MRC1 mRNA]; BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of MRC1 protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of IL1B protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of IL6 protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of TNF protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of CD86 mRNA]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of CD86 protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased phosphorylation of JAK2 protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased phosphorylation of STAT3 protein]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of and results in decreased secretion of IL10 protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of ARG1 mRNA]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of ARG1 protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of MRC1 mRNA]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of MRC1 protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of IL1B protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of IL6 protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of TNF protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of CD86 mRNA]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of CD86 protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 protein]]

NCBI chr11:76,854,090...76,877,389
Ensembl chr11:76,854,090...76,877,389

G

BAF chromatin remodeling complex subunit BCL7C

increases expression

Dextran Sulfate results in increased expression of BCL7C mRNA

NCBI chr 1:182,277,163...182,324,274
Ensembl chr 1:182,260,164...182,324,163

G

bradykinin receptor B1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BDKRB1 mRNA

NCBI chr 6:124,510,827...124,514,475
Ensembl chr 6:124,510,870...124,513,747

G

bradykinin receptor B2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BDKRB2 mRNA

NCBI chr 6:124,472,317...124,502,497
Ensembl chr 6:124,472,566...124,502,497

G

beclin 1

multiple interactions
increases expression

2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Dextran Sulfate co-treated with alpinetin] results in increased expression of BECN1 protein]; [Dextran Sulfate co-treated with 6-formylindolo(3,2-b)carbazole] results in increased expression of BECN1 protein; [Dextran Sulfate co-treated with alpinetin] results in increased expression of BECN1 protein; [Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of BECN1 protein; [HU 308 co-treated with Dextran Sulfate] affects the expression of BECN1 protein; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of BECN1 protein]; HU 308 promotes the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of BECN1 protein]; Leucine inhibits the reaction [[Dextran Sulfate co-treated with alpinetin] results in increased expression of BECN1 protein]; Nicotine promotes the reaction [Dextran Sulfate results in increased expression of BECN1 protein]
dorsomorphin inhibits the reaction [Nicotine promotes the reaction [Dextran Sulfate results in increased expression of BECN1 protein]]; Nicotine promotes the reaction [Dextran Sulfate results in increased expression of BECN1 protein]

PMID:27611972 PMID:31676321 PMID:31926917

NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742

G

bestrophin 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BEST1 mRNA

NCBI chr 1:206,629,340...206,646,085
Ensembl chr 1:206,629,500...206,646,063

G

biglycan

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BGN mRNA

NCBI chr X:151,197,296...151,209,458
Ensembl chr X:151,197,273...151,209,461

G

bridging integrator 2

decreases expression

Dextran Sulfate results in decreased expression of BIN2 protein

NCBI chr 7:131,742,001...131,768,208
Ensembl chr 7:131,742,002...131,786,285

G

baculoviral IAP repeat-containing 5

multiple interactions

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BIRC5 protein; Aspirin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BIRC5 protein]; Camptothecin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BIRC5 protein]; Plant Extracts inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BIRC5 protein]

NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380

G

baculoviral IAP repeat-containing 6

decreases expression

Dextran Sulfate results in decreased expression of BIRC6 mRNA

NCBI chr 6:20,722,922...20,916,396
Ensembl chr 6:20,722,922...20,916,434

G

bone morphogenetic protein 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BMP1 mRNA

NCBI chr15:45,551,603...45,595,862
Ensembl chr15:45,551,603...45,595,776

G

bone morphogenetic protein 10

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BMP10 mRNA

NCBI chr 4:119,872,066...119,877,694
Ensembl chr 4:119,872,045...119,878,627

G

bone morphogenetic protein 7

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BMP7 mRNA

NCBI chr 3:161,639,915...161,716,938
Ensembl chr 3:161,516,462...161,716,788

G

bone morphogenetic protein receptor type 1B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BMPR1B mRNA

NCBI chr 2:230,538,252...230,871,077
Ensembl chr 2:230,541,558...230,871,368

G

bone morphogenetic protein receptor type 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BMPR2 mRNA

NCBI chr 9:61,192,718...61,307,280
Ensembl chr 9:61,190,566...61,301,809

G

BPI fold containing family A, member 1

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in increased expression of BPIFA1 protein

NCBI chr 3:142,627,810...142,633,553
Ensembl chr 3:142,627,810...142,633,552

G

B-box and SPRY domain containing

increases expression

Dextran Sulfate results in increased expression of BSPRY mRNA

NCBI chr 5:75,927,397...75,949,585
Ensembl chr 5:75,927,405...75,949,583

G

bone marrow stromal cell antigen 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BST1 mRNA

NCBI chr14:67,253,706...67,270,203
Ensembl chr14:67,252,998...67,270,180

G

basic transcription factor 3-like 4

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of BTF3L4 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of BTF3L4 protein]

NCBI chr 5:123,567,902...123,587,527
Ensembl chr 5:123,567,907...123,586,866

G

core 1 synthase, glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase, 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of C1GALT1 mRNA

NCBI chr 4:35,930,981...35,966,100
Ensembl chr 4:35,928,104...35,961,831

G

C1GALT1-specific chaperone 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of C1GALT1C1 mRNA

NCBI chr X:117,378,123...117,382,620
Ensembl chr X:117,375,525...117,382,787

G

complement C1q A chain

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C1QA mRNA

NCBI chr 5:149,133,635...149,136,482
Ensembl chr 5:149,133,636...149,136,534

G

complement C1q B chain

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C1QB mRNA

NCBI chr 5:149,118,843...149,124,394
Ensembl chr 5:149,118,846...149,124,407

G

C1q and TNF related 6

decreases expression

Dextran Sulfate results in decreased expression of C1QTNF6 mRNA

NCBI chr 7:110,077,867...110,084,584
Ensembl chr 7:110,077,878...110,084,412

G

complement C1s

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C1S1 mRNA

NCBI chr 4:157,430,249...157,442,438
Ensembl chr 4:157,430,117...157,442,303

G

complement C3

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in increased expression of C3 protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C3 mRNA

PMID:29950665 PMID:35999755

NCBI chr 9:2,087,437...2,114,366
Ensembl chr 9:2,087,437...2,114,429

G

complement C3a receptor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C3AR1 mRNA

NCBI chr 4:156,074,747...156,084,680
Ensembl chr 4:156,075,389...156,084,701

G

complement C4B

multiple interactions
increases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C4B mRNA; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of C4B protein]

PMID:29950665 PMID:32272095

NCBI chr20:4,197,371...4,211,684
Ensembl chr20:4,197,366...4,211,681

G

complement component 4 binding protein, alpha

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in increased expression of C4BPA protein

NCBI chr13:42,075,715...42,111,205
Ensembl chr13:42,075,717...42,111,205

G

complement C5a receptor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C5AR1 mRNA

NCBI chr 1:76,948,622...76,959,826

G

calcium binding protein 39

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CAB39 mRNA

NCBI chr 9:86,463,095...86,524,545
Ensembl chr 9:86,463,095...86,524,544

G

calcium voltage-gated channel subunit alpha1 F

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CACNA1F mRNA

NCBI chr X:14,868,096...14,896,413
Ensembl chr X:14,868,024...14,896,413

G

calcium voltage-gated channel subunit alpha1 S

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CACNA1S mRNA

NCBI chr13:47,493,949...47,564,194
Ensembl chr13:47,493,949...47,564,318

G

calcitonin-related polypeptide alpha

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CALCA mRNA

NCBI chr 1:168,878,212...168,883,176
Ensembl chr 1:168,878,214...168,883,105

G

calcitonin-related polypeptide, beta

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CALCB mRNA

NCBI chr 1:168,965,383...168,970,259
Ensembl chr 1:168,966,465...168,970,125

G

calmodulin 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CALM1 mRNA

NCBI chr 6:119,487,691...119,495,759
Ensembl chr 6:119,487,621...119,498,227

G

calmodulin 2

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of CALM2 protein
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of CALM2 protein

NCBI chr 6:7,091,624...7,104,284
Ensembl chr 6:7,091,567...7,104,287
Ensembl chr15:7,091,567...7,104,287

G

calreticulin

decreases expression

Dextran Sulfate results in decreased expression of CALR protein

NCBI chr19:23,308,525...23,313,420
Ensembl chr19:23,308,351...23,313,414

G

calcium/calmodulin-dependent protein kinase II gamma

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CAMK2G mRNA

NCBI chr15:3,504,017...3,563,050
Ensembl chr15:3,504,085...3,563,050

G

calcium/calmodulin-dependent protein kinase IV

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CAMK4 mRNA

NCBI chr18:24,582,988...24,811,918
Ensembl chr18:24,585,269...24,802,487

G

calcium/calmodulin-dependent protein kinase kinase 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CAMKK1 mRNA

NCBI chr10:57,637,335...57,660,498
Ensembl chr10:57,637,391...57,660,498

G

cyclase associated actin cytoskeleton regulatory protein 1

decreases expression

Dextran Sulfate results in decreased expression of CAP1 protein

NCBI chr 5:135,142,108...135,168,885
Ensembl chr 5:135,142,112...135,168,769

G

calpain 13

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CAPN13 protein]

NCBI chr 6:22,071,845...22,166,864
Ensembl chr 6:22,071,845...22,166,850

G

capping actin protein of muscle Z-line subunit beta

decreases expression

Dextran Sulfate results in decreased expression of CAPZB protein

NCBI chr 5:151,435,600...151,535,409
Ensembl chr 5:151,434,871...151,535,409

G

carbonic anhydrase 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CAR2 mRNA

NCBI chr 2:86,741,625...86,756,766
Ensembl chr 2:86,741,626...86,756,818

G

carbonic anhydrase 3

multiple interactions
increases expression

Erianin inhibits the reaction [Dextran Sulfate results in increased expression of CA3 protein]

NCBI chr 2:86,770,418...86,780,011
Ensembl chr 2:86,770,420...86,784,280

G

carbonic anhydrase 4

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CA4 protein]

NCBI chr10:69,827,945...69,836,501
Ensembl chr10:69,827,945...69,836,501

G

caspase 1

multiple interactions
increases expression

3-methyladenine affects the reaction [[HU 308 co-treated with Dextran Sulfate] affects the cleavage of CASP1 protein]; [Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein; [Dextran Sulfate co-treated with Zearalenone] results in increased expression of CASP1 mRNA; [Dextran Sulfate co-treated with Zearalenone] results in increased expression of CASP1 protein; [HU 308 co-treated with Dextran Sulfate] affects the cleavage of CASP1 protein; [Streptozocin co-treated with Dextran Sulfate] results in increased cleavage of CASP1 protein; ATG5 protein affects the reaction [HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]; Dextran Sulfate results in increased activity of and results in increased cleavage of CASP1 protein; dorsomorphin inhibits the reaction [HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]]; HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]; hydroxysafflor yellow A inhibits the reaction [Dextran Sulfate results in increased activity of and results in increased cleavage of CASP1 protein]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased activity of and results in increased cleavage of CASP1 protein]
Dextran Sulfate results in increased expression of CASP1 mRNA; Dextran Sulfate results in increased expression of CASP1 protein
celastrol inhibits the reaction [Dextran Sulfate results in increased expression of CASP1 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [Dextran Sulfate results in increased expression of CASP1 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide promotes the reaction [celastrol inhibits the reaction [Dextran Sulfate results in increased expression of CASP1 protein]]

PMID:27611972 PMID:30270565 PMID:32470352 PMID:34964214 PMID:37001609

NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383

G

caspase 3

increases cleavage
multiple interactions
increases activity

Dextran Sulfate results in increased cleavage of CASP3 protein
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [alpinetin inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein]]; 6-formylindolo(3,2-b)carbazole inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein]; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CASP3 mRNA; alpinetin inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein]; biochanin A inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein]; daphnetin inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein]; EIF2AK2 protein affects the reaction [Dextran Sulfate results in increased activity of CASP3 protein]; gingerol inhibits the reaction [Dextran Sulfate results in increased activity of CASP3 protein]; Leucine inhibits the reaction [alpinetin inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein]]; Plant Extracts inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased activity of CASP3 protein]

PMID:21989142 PMID:27920257 PMID:28421826 PMID:29950665 PMID:31676321 More...

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 8

multiple interactions
decreases expression

dihydrotanshinone I inhibits the reaction [Dextran Sulfate results in decreased expression of CASP8 protein]

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

G

catalase

decreases activity
multiple interactions
increases activity

Dextran Sulfate results in decreased activity of CAT protein
[Streptozocin co-treated with Dextran Sulfate] results in decreased expression of CAT protein; Fatty Acids, Omega-3 inhibits the reaction [Dextran Sulfate results in increased activity of CAT protein]; gingerol inhibits the reaction [Dextran Sulfate results in decreased activity of CAT protein]; mangiferin inhibits the reaction [Dextran Sulfate results in decreased activity of CAT protein]; Qingdai compound inhibits the reaction [Dextran Sulfate results in decreased activity of CAT protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in decreased activity of CAT protein]

PMID:27125760 PMID:28421826 PMID:30489199 PMID:31737179 PMID:34964214

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

caveolae associated protein 2

decreases expression

Dextran Sulfate results in decreased expression of CAVIN2 protein

NCBI chr 9:50,302,079...50,314,096
Ensembl chr 9:50,301,206...50,314,147

G

carbonyl reductase 1

decreases expression

Dextran Sulfate results in decreased expression of CBR1 protein

NCBI chr11:32,860,571...32,862,981
Ensembl chr11:32,908,950...32,911,393
Ensembl chr11:32,908,950...32,911,393

G

carbonyl reductase 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CBR3 mRNA

NCBI chr11:33,008,615...33,016,877
Ensembl chr11:33,008,615...33,016,875

G

coiled-coil domain containing 12

increases expression

Dextran Sulfate results in increased expression of CCDC12 mRNA

NCBI chr 8:110,635,276...110,686,417
Ensembl chr 8:110,635,710...110,686,417

G

coiled-coil domain containing 124

increases expression

Dextran Sulfate results in increased expression of CCDC124 mRNA

NCBI chr16:18,566,745...18,572,564
Ensembl chr16:18,566,745...18,572,564

G

coiled-coil domain containing 13

increases expression

Dextran Sulfate results in increased expression of CCDC13 mRNA

NCBI chr 8:121,455,202...121,507,487
Ensembl chr 8:121,457,697...121,502,337

G

coiled-coil domain containing 158

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of CCDC158 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CCDC158 protein]

NCBI chr14:15,411,178...15,468,579
Ensembl chr14:15,411,163...15,468,581

G

coiled-coil domain containing 88B

increases expression

Dextran Sulfate results in increased expression of CCDC88B mRNA

NCBI chr 1:204,036,913...204,052,878
Ensembl chr 1:204,036,918...204,052,970

G

coiled-coil domain containing 9

increases expression

Dextran Sulfate results in increased expression of CCDC9 mRNA

NCBI chr 1:76,978,312...76,991,673
Ensembl chr 1:76,974,091...76,991,607

G

coiled-coil domain containing 96

increases expression

Dextran Sulfate results in increased expression of CCDC96 mRNA

NCBI chr14:74,276,568...74,279,072
Ensembl chr14:74,276,960...74,278,888

G

coiled-coil alpha-helical rod protein 1

increases expression

Dextran Sulfate results in increased expression of CCHCR1 mRNA

NCBI chr20:3,205,675...3,218,437
Ensembl chr20:3,205,676...3,218,308

G

cholecystokinin B receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CCKBR mRNA

NCBI chr 1:159,771,733...159,781,738
Ensembl chr 1:159,771,733...159,814,881

G

C-C motif chemokine ligand 11

increases secretion
increases expression
multiple interactions

Dextran Sulfate results in increased secretion of CCL11 protein
Dextran Sulfate results in increased expression of CCL11 mRNA
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL11 mRNA; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of CCL11 mRNA]; Tetrachlorodibenzodioxin inhibits the reaction [Dextran Sulfate results in increased secretion of CCL11 protein]

PMID:21858153 PMID:29950665 PMID:32033881

NCBI chr10:67,028,328...67,032,929
Ensembl chr10:67,028,328...67,032,926

G

C-C motif chemokine ligand 2

multiple interactions
increases expression
increases secretion

[RASSF1 gene mutant form results in increased susceptibility to Dextran Sulfate] which results in increased secretion of CCL2 protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL2 mRNA; flavokawain B inhibits the reaction [Dextran Sulfate results in increased expression of CCL2 mRNA]; Tetrachlorodibenzodioxin inhibits the reaction [Dextran Sulfate results in increased secretion of CCL2 protein]

PMID:19645018 PMID:20079348 PMID:21858153 PMID:24146755 PMID:29950665 More...

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

C-C motif chemokine ligand 21

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL21A mRNA

NCBI chr 5:56,980,557...56,981,661
Ensembl chr 5:56,980,558...56,981,686

G

C-C motif chemokine ligand 24

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL24 mRNA

NCBI chr12:21,100,835...21,104,832
Ensembl chr12:21,100,835...21,104,893

G

C-C motif chemokine ligand 25

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CCL25 mRNA

NCBI chr12:2,707,398...2,716,571
Ensembl chr12:2,707,398...2,716,554

G

C-C motif chemokine ligand 27

increases expression

Dextran Sulfate results in increased expression of CCL27A mRNA

NCBI chr 5:56,941,402...56,948,511
Ensembl chr 5:56,941,402...56,948,506

G

C-C motif chemokine ligand 28

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CCL28 mRNA

NCBI chr 2:51,601,354...51,625,999
Ensembl chr 2:51,601,331...51,625,997

G

C-C motif chemokine ligand 3

increases expression
multiple interactions

Dextran Sulfate results in increased expression of CCL3 mRNA
ligustilide inhibits the reaction [Dextran Sulfate results in increased expression of CCL3 mRNA]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased expression of CCL3 mRNA]
Dextran Sulfate results in increased expression of CCL3 protein
Hesperidin inhibits the reaction [Dextran Sulfate results in increased expression of CCL3 protein]

PMID:19645018 PMID:30811821 PMID:33130971

NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938

G

C-C motif chemokine ligand 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL4 mRNA

NCBI chr10:68,466,394...68,468,229
Ensembl chr10:68,452,052...68,468,231

G

C-C motif chemokine ligand 7

increases expression
multiple interactions

Dextran Sulfate results in increased expression of CCL7 mRNA
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL7 mRNA; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of CCL7 mRNA]

PMID:19645018 PMID:29950665 PMID:32033881

NCBI chr10:67,016,446...67,018,296
Ensembl chr10:67,016,446...67,018,303

G

C-C motif chemokine ligand 9

increases expression
decreases expression

Dextran Sulfate results in increased expression of CCL6 mRNA
Dextran Sulfate results in decreased expression of CCL6 mRNA

PMID:19645018 PMID:35093514

NCBI chr10:68,366,486...68,371,408
Ensembl chr10:68,366,487...68,371,369

G

cyclin D1

multiple interactions

[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CCND1 mRNA; [Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CCND1 protein; [Dietary Fats co-treated with Dextran Sulfate] results in decreased expression of CCND1 protein; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CCND1 mRNA]; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CCND1 protein]; obeticholic acid inhibits the reaction [[Dietary Fats co-treated with Dextran Sulfate] results in decreased expression of CCND1 protein]

PMID:31715269 PMID:35439472

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

C-C motif chemokine receptor 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCR2 mRNA

NCBI chr 8:123,734,465...123,742,483
Ensembl chr 8:123,734,430...123,742,100

G

C-C motif chemokine receptor 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCR4 mRNA

NCBI chr 8:114,176,291...114,182,033
Ensembl chr 8:114,176,974...114,178,056

G

C-C motif chemokine receptor 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCR5 mRNA

NCBI chr 8:123,752,423...123,757,538
Ensembl chr 8:123,752,325...123,759,260

G

C-C motif chemokine receptor 7

multiple interactions

Melatonin inhibits the reaction [Dextran Sulfate results in increased expression of CCR7 mRNA]; Melatonin inhibits the reaction [Dextran Sulfate results in increased expression of CCR7 protein]

NCBI chr10:84,098,193...84,108,309
Ensembl chr10:84,097,381...84,108,309

G

C-C motif chemokine receptor 8

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCR8 mRNA

NCBI chr 8:119,826,332...119,828,292
Ensembl chr 8:119,826,568...119,827,629

G

C-C motif chemokine receptor like 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCRL2 mRNA

NCBI chr 8:111,034,279...111,036,914
Ensembl chr 8:111,034,279...111,036,664

G

centriole, cilia and spindle-associated protein

increases expression

Dextran Sulfate results in increased expression of CCSAP mRNA

NCBI chr19:51,824,954...51,843,469
Ensembl chr19:51,826,994...51,842,753

G

CD14 molecule

affects response to substance
multiple interactions

Dextran Sulfate affects the susceptibility to CD14 protein
[Dextran Sulfate affects the susceptibility to CD14 protein] which affects the expression of IFNG mRNA; CD14 protein inhibits the reaction [Dextran Sulfate results in increased expression of TNF mRNA]

NCBI chr18:28,335,522...28,337,383
Ensembl chr18:28,335,340...28,337,261

G

CD163 molecule

increases expression

Dextran Sulfate results in increased expression of CD163 mRNA

NCBI chr 4:157,085,080...157,118,470
Ensembl chr 4:157,085,093...157,117,878

G

CD177 molecule

increases expression

Dextran Sulfate results in increased expression of CD177 mRNA

NCBI chr 1:80,340,034...80,360,599
Ensembl chr 1:80,340,034...80,360,621

G

CD180 molecule

increases expression
multiple interactions

Dextran Sulfate results in increased expression of CD180 mRNA
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD180 mRNA

PMID:23894361 PMID:29950665

NCBI chr 2:33,855,940...33,870,046
Ensembl chr 2:33,855,991...33,899,936

G

CD19 molecule

increases expression

Dextran Sulfate results in increased expression of CD19 mRNA

NCBI chr 1:180,987,286...180,993,920
Ensembl chr 1:180,987,286...180,993,975

G

Cd200 molecule

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD200 mRNA

NCBI chr11:55,410,166...55,437,527
Ensembl chr11:55,410,196...55,501,648

G

Cd247 molecule

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD247 mRNA

NCBI chr13:78,043,302...78,118,437
Ensembl chr13:78,043,307...78,122,263

G

CD274 molecule

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD274 mRNA

NCBI chr 1:227,116,674...227,137,379
Ensembl chr 1:227,116,649...227,134,450

G

Cd28 molecule

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD28 mRNA

NCBI chr 9:62,166,324...62,194,674
Ensembl chr 9:62,166,192...62,194,685

G

CD34 molecule

decreases expression

Dextran Sulfate results in decreased expression of CD34 mRNA

NCBI chr13:106,480,313...106,500,844
Ensembl chr13:106,480,043...106,499,832

G

Cd4 molecule

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD4 mRNA

NCBI chr 4:157,668,878...157,695,366

G

CD44 molecule

multiple interactions

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of CD44 mRNA

NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620

G

CD52 molecule

increases expression

Dextran Sulfate results in increased expression of CD52 mRNA

NCBI chr 5:146,319,789...146,321,348
Ensembl chr 5:146,319,969...146,321,348

G

Cd53 molecule

increases expression

Dextran Sulfate results in increased expression of CD53 mRNA

NCBI chr 2:194,352,139...194,399,668
Ensembl chr 2:194,352,139...194,399,657

G

CD55 molecule (Cromer blood group)

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD55 mRNA

NCBI chr13:41,857,242...41,885,966
Ensembl chr13:41,857,395...41,885,831

G

Cd68 molecule

increases expression

dextran sulfate increases expression of CD68 protein in colonic lamina propria of mice

RGD

NCBI chr10:54,381,814...54,383,693
Ensembl chr10:54,381,815...54,383,697

G

Cd72 molecule

increases expression

Dextran Sulfate results in increased expression of CD72 mRNA

NCBI chr 5:57,697,361...57,704,980
Ensembl chr 5:57,697,367...57,704,725

G

CD74 molecule

increases expression
decreases expression

Dextran Sulfate results in increased expression of CD74 mRNA
Dextran Sulfate results in decreased expression of CD74 mRNA

PMID:23894361 PMID:35093514

NCBI chr18:54,256,757...54,266,003
Ensembl chr18:54,256,778...54,266,003

G

CD79a molecule

increases expression

Dextran Sulfate results in increased expression of CD79A mRNA

NCBI chr 1:80,493,581...80,497,936
Ensembl chr 1:80,493,581...80,497,935

G

CD79b molecule

increases expression

Dextran Sulfate results in increased expression of CD79B mRNA

NCBI chr10:91,239,354...91,242,500
Ensembl chr10:91,239,356...91,242,625

G

Cd81 molecule

decreases expression

Dextran Sulfate results in decreased expression of CD81 mRNA

NCBI chr 1:198,235,861...198,251,660
Ensembl chr 1:198,241,484...198,251,660

G

CD86 molecule

multiple interactions
increases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD86 mRNA; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of CD86 mRNA]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of CD86 protein]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of CD86 mRNA]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of CD86 protein]]; IRF4 protein promotes the reaction [Dextran Sulfate results in increased expression of CD86 mRNA]; IRF4 protein promotes the reaction [Dextran Sulfate results in increased expression of CD86 protein]
Dextran Sulfate results in increased expression of CD86 mRNA; Dextran Sulfate results in increased expression of CD86 protein

PMID:29950665 PMID:38164749

NCBI chr11:64,142,193...64,200,816
Ensembl chr11:64,163,828...64,200,818

G

cytidine deaminase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CDA mRNA

NCBI chr 5:150,556,615...150,583,231
Ensembl chr 5:150,556,615...150,583,231

G

cadherin 1

multiple interactions
decreases expression

7-hydroxyl-1-methylindole-3-acetonitrile inhibits the reaction [Dextran Sulfate results in decreased expression of CDH1 protein]; [Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CDH1 protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CDH1 mRNA
Dextran Sulfate results in decreased expression of CDH1 mRNA; Dextran Sulfate results in decreased expression of CDH1 protein

PMID:29950665 PMID:34273909 PMID:36543318 PMID:37385329

NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775

G

cadherin 2

multiple interactions
increases expression

7-hydroxyl-1-methylindole-3-acetonitrile inhibits the reaction [Dextran Sulfate results in increased expression of CDH2 protein]; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CDH2 protein

PMID:34273909 PMID:36543318

NCBI chr18:7,776,704...7,990,934
Ensembl chr18:7,776,704...7,990,167

G

cadherin 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CDH5 mRNA

NCBI chr19:815,415...854,478
Ensembl chr19:815,411...854,368

G

cadherin-related family member 2

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of CDHR2 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CDHR2 protein]

NCBI chr17:9,876,853...9,913,356
Ensembl chr17:9,876,860...9,912,575

G

cyclin-dependent kinase 11B

increases expression

Dextran Sulfate results in increased expression of CDK11B mRNA

NCBI chr 5:166,212,761...166,238,883
Ensembl chr 5:166,212,829...166,238,876

G

cyclin-dependent kinase inhibitor 1C

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CDKN1C mRNA

NCBI chr 1:198,655,394...198,658,097
Ensembl chr 1:198,655,407...198,658,048

G

caudal type homeo box 2

increases expression
decreases expression
multiple interactions

Dextran Sulfate results in increased expression of CDX2 protein
Dextran Sulfate results in decreased expression of CDX2 protein
6-formylindolo(3,2-b)carbazole inhibits the reaction [Dextran Sulfate results in increased expression of CDX2 protein]; nitazoxanide inhibits the reaction [Dextran Sulfate results in decreased expression of CDX2 protein]

PMID:29680209 PMID:38663798

NCBI chr12:7,726,798...7,733,142
Ensembl chr12:7,726,798...7,733,142

G

CCAAT/enhancer binding protein delta

increases expression

Dextran Sulfate results in increased expression of CEBPD mRNA

NCBI chr11:84,764,670...84,765,808
Ensembl chr11:84,764,565...84,765,829

G

carboxyl ester lipase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CEL mRNA

NCBI chr 3:11,883,532...11,891,035
Ensembl chr 3:11,883,532...11,891,035

G

centrosomal protein 131

increases expression

Dextran Sulfate results in increased expression of CEP131 mRNA

NCBI chr10:105,346,015...105,370,380
Ensembl chr10:105,346,015...105,370,380

G

carboxylesterase 1D

multiple interactions
decreases expression

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of CES1D protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CES1D mRNA
Dextran Sulfate results in decreased expression of CES1D mRNA

PMID:29950665 PMID:35093514 PMID:35999755

NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035

G

carboxylesterase 2C

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CES2C mRNA

NCBI chr 1:260,391,190...260,398,757
Ensembl chr 1:260,388,902...260,398,790

G

carboxylesterase 2E

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CES2E mRNA

NCBI chr19:157,447...172,822
Ensembl chr19:157,407...172,856

G

cilia and flagella associated protein 45

increases expression

Dextran Sulfate results in increased expression of CFAP45 mRNA

NCBI chr13:84,989,474...85,012,880
Ensembl chr13:84,981,728...85,012,878

G

complement factor B

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in increased expression of CFB protein

NCBI chr20:3,970,643...3,976,510
Ensembl chr20:3,951,474...3,976,505

G

complement factor D

increases expression

Dextran Sulfate results in increased expression of CFD protein

NCBI chr 7:9,813,148...9,814,871
Ensembl chr 7:9,813,150...9,815,053

G

complement factor H

multiple interactions
increases expression

[Dextran Sulfate co-treated with bisphenol A] results in increased expression of CFH protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CFH mRNA; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of CFH protein]
Dextran Sulfate results in increased expression of CFH mRNA; Dextran Sulfate results in increased expression of CFH protein

PMID:29950665 PMID:32272095 PMID:35093514 PMID:35999755

NCBI chr13:51,512,376...51,613,829
Ensembl chr13:51,511,828...51,613,838

G

cofilin 1

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of CFL1 protein
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of CFL1 protein

NCBI chr 1:202,796,012...202,801,337
Ensembl chr 1:202,786,627...202,817,587

G

CASP8 and FADD-like apoptosis regulator

multiple interactions

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CFLAR protein; Aspirin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CFLAR protein]; Camptothecin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CFLAR protein]; Plant Extracts inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CFLAR protein]

NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034

G

CF transmembrane conductance regulator

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CFTR mRNA

NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756

G

cell growth regulator with EF hand domain 1

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in increased expression of CGREF1 protein

NCBI chr 6:25,431,846...25,443,853
Ensembl chr 6:25,431,799...25,443,852

G

chromatin assembly factor 1 subunit A

increases expression

Dextran Sulfate results in increased expression of CHAF1A mRNA

NCBI chr 9:873,953...900,701
Ensembl chr 9:874,051...900,654

G

calcium homeostasis endoplasmic reticulum protein

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CHERP protein]

NCBI chr16:17,367,455...17,380,507
Ensembl chr16:17,367,455...17,380,507

G

charged multivesicular body protein 2A

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of CHMP2A protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CHMP2A protein]

NCBI chr 1:73,660,045...73,662,894
Ensembl chr 1:73,660,046...73,662,452

G

charged multivesicular body protein 4B

increases expression

Dextran Sulfate results in increased expression of CHMP4B mRNA

NCBI chr 3:143,170,859...143,211,376
Ensembl chr 3:143,170,902...143,210,844

G

chimerin 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CHN2 mRNA

NCBI chr 4:83,148,616...83,407,711
Ensembl chr 4:83,147,983...83,407,709

G

chordin-like 2

increases expression

Dextran Sulfate results in increased expression of CHRDL2 mRNA

NCBI chr 1:154,343,201...154,370,651
Ensembl chr 1:154,343,201...154,370,640

G

cholinergic receptor, muscarinic 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CHRM4 mRNA

NCBI chr 3:77,893,425...77,901,166
Ensembl chr 3:77,893,425...77,901,159

G

cholinergic receptor nicotinic alpha 2 subunit

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CHRNA2 mRNA

NCBI chr15:40,342,317...40,358,601
Ensembl chr15:40,342,317...40,358,601

G

cholinergic receptor nicotinic alpha 7 subunit

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CHRNA7 mRNA

NCBI chr 1:116,711,559...116,837,269
Ensembl chr 1:116,714,711...116,837,240

G

cholinergic receptor nicotinic beta 3 subunit

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CHRNB3 mRNA

NCBI chr16:64,713,438...64,751,360
Ensembl chr16:64,714,169...64,751,360

G

cholinergic receptor nicotinic epsilon subunit

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CHRNE mRNA

NCBI chr10:55,331,211...55,339,923
Ensembl chr10:55,331,212...55,335,530

G

carbohydrate sulfotransferase 11

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CHST11 mRNA

NCBI chr 7:20,524,535...20,743,008
Ensembl chr 7:20,528,100...20,743,111

G

component of inhibitor of nuclear factor kappa B kinase complex

increases expression
multiple interactions

Dextran Sulfate results in increased expression of CHUK protein modified form
notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of CHUK protein modified form]

NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065

G

creatine kinase B

decreases expression

Dextran Sulfate results in decreased expression of CKB protein

NCBI chr 6:130,729,420...130,732,301
Ensembl chr 6:130,729,423...130,732,315

G

creatine kinase, M-type

decreases expression

Dextran Sulfate results in decreased expression of CKM protein

NCBI chr 1:79,061,390...79,071,721
Ensembl chr 1:79,061,456...79,071,720

G

chloride channel accessory 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CLCA1 mRNA

NCBI chr 2:233,938,677...233,964,369
Ensembl chr 2:233,938,677...233,964,369

G

chloride channel accessory 4

increases expression

Dextran Sulfate results in increased expression of CLCA4 mRNA

NCBI chr 2:233,883,625...233,904,993
Ensembl chr 2:233,883,851...233,903,089

G

chloride voltage-gated channel 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CLCN2 mRNA

NCBI chr11:80,197,741...80,211,657
Ensembl chr11:80,198,153...80,211,657

G

chloride voltage-gated channel 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CLCN3 mRNA

NCBI chr16:29,127,152...29,200,133
Ensembl chr16:29,127,419...29,200,119

G

claudin 1

multiple interactions
increases expression
decreases expression

7-hydroxyl-1-methylindole-3-acetonitrile inhibits the reaction [Dextran Sulfate results in increased expression of CLDN1 protein]; [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone co-treated with Dextran Sulfate] results in decreased expression of CLDN1 protein; [SB 203580 co-treated with Dextran Sulfate] results in decreased expression of CLDN1 protein; biochanin A inhibits the reaction [Dextran Sulfate results in decreased expression of CLDN1 protein]; hydroxysafflor yellow A inhibits the reaction [Dextran Sulfate results in decreased expression of CLDN1 protein]

PMID:27920472 PMID:36543318 PMID:37001609 PMID:38648921

NCBI chr11:74,421,569...74,436,728
Ensembl chr11:74,421,569...74,436,724

G

claudin 11

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CLDN11 mRNA

NCBI chr 2:112,207,745...112,221,050
Ensembl chr 2:112,207,745...112,221,050

G

claudin 2

multiple interactions
increases expression

6-formylindolo(3,2-b)carbazole inhibits the reaction [Dextran Sulfate results in increased expression of CLDN2 mRNA]; 6-formylindolo(3,2-b)carbazole inhibits the reaction [Dextran Sulfate results in increased expression of CLDN2 protein]; 7-hydroxyl-1-methylindole-3-acetonitrile inhibits the reaction [Dextran Sulfate results in increased expression of CLDN2 protein]; [Benzo(a)pyrene co-treated with Dextran Sulfate] results in decreased expression of CLDN2 mRNA
Dextran Sulfate results in increased expression of CLDN2 mRNA; Dextran Sulfate results in increased expression of CLDN2 protein

PMID:26271895 PMID:29680209 PMID:36543318

NCBI chr X:103,459,870...103,473,794
Ensembl chr X:103,459,780...103,474,838

G

C-type lectin domain containing 10A

increases expression

Dextran Sulfate results in increased expression of CLEC10A mRNA

NCBI chr10:54,876,244...54,880,439
Ensembl chr10:54,876,260...54,880,435

G

chloride intracellular channel 1

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of CLIC1 protein
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of CLIC1 protein

NCBI chr20:3,764,867...3,773,711
Ensembl chr20:3,761,461...3,773,712

G

chymase 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CMA1 mRNA

NCBI chr15:29,417,451...29,420,233
Ensembl chr15:29,417,451...29,420,233

G

cytidine monophosphate N-acetylneuraminic acid synthetase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CMAS mRNA

NCBI chr 4:175,718,808...175,737,128
Ensembl chr 4:175,718,808...175,737,125

G

cytidine/uridine monophosphate kinase 1

decreases expression

Dextran Sulfate results in decreased expression of CMPK1 protein

NCBI chr 5:128,480,301...128,507,830
Ensembl chr 5:128,480,301...128,507,830

G

cyclic nucleotide gated channel subunit alpha 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CNGA4 mRNA

NCBI chr 1:159,752,357...159,756,369
Ensembl chr 1:159,752,357...159,756,375

G

calponin 2

decreases expression

Dextran Sulfate results in decreased expression of CNN2 protein

NCBI chr 7:9,712,505...9,719,678
Ensembl chr 7:9,712,516...9,719,656

G

cannabinoid receptor 1

decreases response to substance
multiple interactions
increases expression

CNR1 results in decreased susceptibility to Dextran Sulfate
SB 203580 inhibits the reaction [Dextran Sulfate results in increased expression of CNR1 protein]; Serotonin inhibits the reaction [Dextran Sulfate results in increased expression of CNR1 protein]

PMID:15085199 PMID:27920472 PMID:30611738

NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099

G

cannabinoid receptor 2

multiple interactions
increases response to substance
affects response to substance
increases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CNR2 mRNA; CNR2 gene mutant form promotes the reaction [Dextran Sulfate results in increased secretion of MPO protein]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in decreased expression of SQSTM1 protein]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of and results in increased secretion of IL1B protein]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of BECN1 protein]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of IL1B mRNA]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of NLRP3 protein]; CNR2 protein affects the reaction [Dextran Sulfate results in decreased phosphorylation of MTOR protein]; CNR2 protein affects the reaction [Dextran Sulfate results in decreased phosphorylation of RPS6KB1 protein]; CNR2 protein affects the susceptibility to [Azoxymethane co-treated with Dextran Sulfate]; SB 203580 inhibits the reaction [Dextran Sulfate results in increased expression of CNR2 protein]
CNR2 gene mutant form results in increased susceptibility to Dextran Sulfate
CNR2 protein affects the susceptibility to Dextran Sulfate

PMID:27611972 PMID:27920472 PMID:29950665 PMID:30102254 PMID:32942172

NCBI chr 5:148,125,222...148,151,548
Ensembl chr 5:148,125,604...148,151,548

G

ciliary neurotrophic factor receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CNTFR mRNA

NCBI chr 5:56,823,448...56,861,049
Ensembl chr 5:56,823,965...56,841,392

G

contactin 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CNTN1 mRNA

NCBI chr 7:123,263,146...123,560,896
Ensembl chr 7:123,372,792...123,558,541

G

component of oligomeric golgi complex 1

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of COG1 protein]

NCBI chr10:98,695,481...98,708,495
Ensembl chr10:98,695,423...98,709,292

G

collagen type XI alpha 1 chain

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL11A1 mRNA

NCBI chr 2:201,820,715...202,013,853
Ensembl chr 2:201,820,715...202,013,853

G

collagen type XIV alpha 1 chain

multiple interactions
increases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL14A1 mRNA; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of COL14A1 protein]

PMID:29950665 PMID:32272095

NCBI chr 7:86,722,093...86,937,215
Ensembl chr 7:86,722,094...86,937,214

G

collagen type XVI alpha 1 chain

increases expression

Dextran Sulfate results in increased expression of COL16A1 mRNA

NCBI chr 5:142,388,376...142,442,825
Ensembl chr 5:142,388,426...142,442,825

G

collagen type XVIII alpha 1 chain

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL18A1 mRNA

NCBI chr20:11,474,104...11,582,593
Ensembl chr20:11,474,104...11,582,593

G

collagen type I alpha 1 chain

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL1A1 mRNA
Dextran Sulfate results in decreased expression of COL1A1 mRNA

PMID:29950665 PMID:35093514

NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624

G

collagen type I alpha 2 chain

decreases expression

Dextran Sulfate results in decreased expression of COL1A2 mRNA

NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867

G

collagen type XXII alpha 1 chain

increases expression

Dextran Sulfate results in increased expression of COL22A1 mRNA

NCBI chr 7:103,730,939...103,968,452
Ensembl chr 7:103,731,037...103,968,462

G

collagen type XXIII alpha 1 chain

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL23A1 mRNA

NCBI chr10:35,549,090...35,839,152
Ensembl chr10:35,549,113...35,836,314

G

collagen type XXVIII alpha 1 chain

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL28A1 mRNA

NCBI chr 4:36,069,980...36,223,128
Ensembl chr 4:36,069,970...36,223,220

G

collagen type III alpha 1 chain

decreases expression

Dextran Sulfate results in decreased expression of COL3A1 mRNA

NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547

G

collagen type IV alpha 1 chain

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL4A1 mRNA

NCBI chr16:78,183,533...78,294,412
Ensembl chr16:78,183,533...78,294,412

G

collagen type IV alpha 2 chain

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL4A2 mRNA; Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of COL4A2 protein]

PMID:29950665 PMID:32272095

NCBI chr16:78,047,591...78,183,360
Ensembl chr16:78,047,602...78,183,839

G

collagen type V alpha 1 chain

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL5A1 mRNA

NCBI chr 3:11,208,429...11,356,715
Ensembl chr 3:11,208,512...11,354,588

G

collagen type V alpha 2 chain

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL5A2 mRNA

NCBI chr 9:47,448,741...47,598,134
Ensembl chr 9:47,448,736...47,598,154

G

collagen type VI alpha 1 chain

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of COL6A1 protein]
Dextran Sulfate results in decreased expression of COL6A1 mRNA; Dextran Sulfate results in decreased expression of COL6A1 protein

PMID:32272095 PMID:35093514

NCBI chr20:11,906,105...11,924,599
Ensembl chr20:11,905,957...11,924,597

G

collagen type VI alpha 2 chain

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of COL6A2 mRNA; Dextran Sulfate results in decreased expression of COL6A2 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of COL6A2 protein]

PMID:32272095 PMID:35093514

NCBI chr20:12,021,676...12,049,425
Ensembl chr20:12,021,767...12,057,564

G

collagen type VIII alpha 1 chain

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL8A1 mRNA

NCBI chr11:42,776,851...42,906,432
Ensembl chr11:42,777,628...42,906,424

G

coronin 1A

decreases expression

Dextran Sulfate results in decreased expression of CORO1A protein

NCBI chr 1:181,295,561...181,300,566
Ensembl chr 1:181,295,562...181,300,534

G

coronin 1C

decreases expression

Dextran Sulfate results in decreased expression of CORO1C protein

NCBI chr12:42,713,024...42,785,179
Ensembl chr12:42,712,991...42,785,179

G

coactosin-like F-actin binding protein 1

decreases expression

Dextran Sulfate results in decreased expression of COTL1 protein

NCBI chr19:47,871,689...47,906,010
Ensembl chr19:47,871,694...47,911,689

G

cytochrome c oxidase subunit 5B

increases expression

Dextran Sulfate results in increased expression of COX5B mRNA

NCBI chr 9:38,921,980...38,923,806
Ensembl chr 9:38,921,967...38,925,052

G

ceruloplasmin

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CP mRNA

NCBI chr 2:102,439,433...102,498,075
Ensembl chr 2:102,439,624...102,498,075

G

carboxypeptidase A1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CPA1 mRNA

NCBI chr 4:59,257,417...59,263,544
Ensembl chr 4:59,257,417...59,263,544

G

carboxypeptidase B2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CPB2 mRNA

NCBI chr15:50,557,722...50,606,569
Ensembl chr15:50,557,717...50,606,556

G

complement C3d receptor 2

increases expression

Dextran Sulfate results in increased expression of CR2 mRNA

NCBI chr13:106,678,579...106,716,595
Ensembl chr13:106,685,413...106,716,235

G

capping protein inhibiting regulator of actin dynamics

increases expression

Dextran Sulfate results in increased expression of CRACD mRNA

NCBI chr14:31,284,066...31,520,103
Ensembl chr14:31,284,184...31,522,431

G

corticotropin releasing hormone receptor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CRHR1 mRNA

NCBI chr10:89,040,186...89,083,481
Ensembl chr10:89,040,203...89,083,481

G

corticotropin releasing hormone receptor 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CRHR2 mRNA

NCBI chr 4:84,222,897...84,265,924
Ensembl chr 4:84,224,002...84,265,904

G

cysteine-rich secretory protein 1

decreases expression

Dextran Sulfate results in decreased expression of CRISP1 protein

NCBI chr 9:20,741,775...20,768,796
Ensembl chr 9:20,741,777...20,768,796

G

cartilage associated protein

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CRTAP mRNA

NCBI chr 8:114,047,929...114,067,636
Ensembl chr 8:114,047,933...114,067,631

G

colony stimulating factor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CSF1 mRNA

NCBI chr 2:195,377,215...195,396,608
Ensembl chr 2:195,377,215...195,411,704

G

colony stimulating factor 2

increases expression
multiple interactions

Dextran Sulfate results in increased expression of CSF2 mRNA; Dextran Sulfate results in increased expression of CSF2 protein
[Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] inhibits the reaction [Dextran Sulfate results in increased expression of CSF2 protein]; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CSF2 mRNA; Polymyxin B inhibits the reaction [Dextran Sulfate results in increased expression of CSF2 protein]; Rutin inhibits the reaction [Dextran Sulfate results in increased expression of CSF2 mRNA]; TLR4 protein affects the reaction [Dextran Sulfate results in increased expression of CSF2 protein]

PMID:15652231 PMID:29950665 PMID:31442584

NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199

G

colony stimulating factor 2 receptor subunit beta

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CSF2RB2 mRNA

NCBI chr 7:109,876,919...109,901,589
Ensembl chr 7:109,886,425...109,904,157

G

colony stimulating factor 3

increases expression
multiple interactions

Dextran Sulfate results in increased expression of CSF3 mRNA
Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of CSF3 mRNA]

NCBI chr10:83,660,787...83,664,569
Ensembl chr10:83,661,207...83,663,603

G

colony stimulating factor 3 receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CSF3R mRNA

NCBI chr 5:138,298,605...138,318,224
Ensembl chr 5:138,301,506...138,317,881

G

catenin beta 1

increases expression
multiple interactions

Dextran Sulfate results in increased expression of CTNNB1 protein
[2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Dextran Sulfate] results in increased expression of CTNNB1 protein; [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Dextran Sulfate] results in increased mutagenesis of CTNNB1 gene; [Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CTNNB1 protein; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CTNNB1 protein]; CTNNB1 gene mutant form results in increased susceptibility to [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Dextran Sulfate]

PMID:15459021 PMID:16049979 PMID:27664423 PMID:31715269

NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111

G

CTP synthase 1

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of CTPS1 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CTPS1 protein]

NCBI chr 5:134,125,022...134,154,155
Ensembl chr 5:134,125,025...134,154,180

G

cathepsin C

decreases expression

Dextran Sulfate results in decreased expression of CTSC mRNA

NCBI chr 1:142,028,386...142,059,841
Ensembl chr 1:142,028,392...142,060,387

G

cathepsin D

multiple interactions
increases expression

Erianin inhibits the reaction [Dextran Sulfate results in increased expression of CTSD protein]

NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488

G

cathepsin K

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CTSK mRNA

NCBI chr 2:183,058,586...183,069,551
Ensembl chr 2:183,058,569...183,069,550

G

cathepsin L

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of CTSL protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CTSL mRNA

PMID:29950665 PMID:35999755

NCBI chr17:764,370...770,533
Ensembl chr17:764,309...770,548

G

cathepsin S

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CTSS protein]

NCBI chr 2:183,086,437...183,114,483
Ensembl chr 2:183,086,437...183,114,483

G

cubilin

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CUBN mRNA

NCBI chr17:76,385,046...76,593,133
Ensembl chr17:76,385,060...76,593,231

G

C-X3-C motif chemokine receptor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CX3CR1 mRNA

NCBI chr 8:119,785,726...119,799,431
Ensembl chr 8:119,782,595...119,800,014

G

CXADR, Ig-like cell adhesion molecule

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CXADR mRNA

NCBI chr11:16,982,864...17,030,078
Ensembl chr11:16,982,860...17,030,046

G

C-X-C motif chemokine ligand 10

multiple interactions

[Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CXCL10 mRNA; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CXCL10 mRNA]

NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975

G

C-X-C motif chemokine ligand 12

decreases expression

Dextran Sulfate results in decreased expression of CXCL12 mRNA

NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168

G

C-X-C motif chemokine ligand 13

increases expression

Dextran Sulfate results in increased expression of CXCL13 mRNA

PMID:23894361 PMID:35093514

NCBI chr14:13,608,894...13,613,965
Ensembl chr14:13,608,902...13,613,933

G

C-X-C motif chemokine ligand 14

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CXCL14 mRNA

NCBI chr17:8,317,930...8,325,956
Ensembl chr17:8,317,933...8,324,839

G

C-X-C motif chemokine ligand 2

multiple interactions
increases expression

17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of CXCL2 protein]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of CXCL2 mRNA]; Benzo(a)pyrene inhibits the reaction [Dextran Sulfate results in increased expression of CXCL2 mRNA]; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of CXCL2 mRNA]; resolvin D1 inhibits the reaction [Dextran Sulfate results in increased expression of CXCL2 protein]; resolvin D2 inhibits the reaction [Dextran Sulfate results in increased expression of CXCL2 protein]
Dextran Sulfate results in increased expression of CXCL2 mRNA; Dextran Sulfate results in increased expression of CXCL2 protein

PMID:21724996 PMID:32033881 PMID:34998820 PMID:36519841

NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075

G

C-X-C motif chemokine ligand 3

multiple interactions
increases secretion
increases expression

17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of CXCL1 protein]; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CXCL1 protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CXCL1 mRNA; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of CXCL1 mRNA]; Benzo(a)pyrene inhibits the reaction [Dextran Sulfate results in increased expression of CXCL1 mRNA]; resolvin D1 inhibits the reaction [Dextran Sulfate results in increased expression of CXCL1 protein]; resolvin D2 inhibits the reaction [Dextran Sulfate results in increased expression of CXCL1 protein]; Tetrachlorodibenzodioxin inhibits the reaction [Dextran Sulfate results in increased secretion of CXCL1 protein]
Dextran Sulfate results in increased expression of CXCL1 mRNA; Dextran Sulfate results in increased expression of CXCL1 protein

PMID:19645018 PMID:20079348 PMID:21724996 PMID:21858153 PMID:29950665 More...

NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511

G

C-X-C motif chemokine ligand 6

multiple interactions
increases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CXCL5 mRNA
Dextran Sulfate results in increased expression of CXCL5 mRNA

PMID:19645018 PMID:29950665

NCBI chr14:17,310,790...17,312,250
Ensembl chr14:17,310,426...17,313,093

G

C-X-C motif chemokine ligand 9

increases expression

Dextran Sulfate results in increased expression of CXCL9 mRNA

NCBI chr14:15,722,868...15,727,779
Ensembl chr14:15,722,908...15,728,435

G

C-X-C motif chemokine receptor 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CXCR2 mRNA

NCBI chr 9:75,729,493...75,735,868
Ensembl chr 9:75,729,115...75,739,425

G

cytochrome b-245 alpha chain

increases expression

Dextran Sulfate results in increased expression of CYBA protein

NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721

G

cytochrome b-245 beta chain

increases expression

Dextran Sulfate results in increased expression of CYBB mRNA; Dextran Sulfate results in increased expression of CYBB protein

PMID:20637373 PMID:23894361

NCBI chr X:13,358,101...13,392,570
Ensembl chr X:13,359,430...13,392,586

G

cytoplasmic FMR1 interacting protein 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CYFIP1 mRNA

NCBI chr 1:106,710,924...106,799,393
Ensembl chr 1:106,711,016...106,799,386

G

cytoplasmic FMR1 interacting protein 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CYFIP2 mRNA

NCBI chr10:30,621,318...30,741,113
Ensembl chr10:30,621,318...30,741,113

G

cytochrome P450, family 11, subfamily a, polypeptide 1

decreases expression

Dextran Sulfate results in decreased expression of CYP11A1 mRNA

NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338

G

cytochrome P450, family 17, subfamily a, polypeptide 1

decreases expression

Dextran Sulfate results in decreased expression of CYP17A1 mRNA

NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions
decreases expression

6-formylindolo(3,2-b)carbazole inhibits the reaction [Dextran Sulfate results in decreased expression of CYP1A1 mRNA]; 6-formylindolo(3,2-b)carbazole inhibits the reaction [Dextran Sulfate results in decreased expression of CYP1A1 protein]; Dextran Sulfate inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA]
Dextran Sulfate results in decreased expression of CYP1A1 mRNA; Dextran Sulfate results in decreased expression of CYP1A1 protein

PMID:29680209 PMID:34998820

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 1, subfamily a, polypeptide 2

multiple interactions
decreases activity

[Dextran Sulfate results in decreased activity of CYP1A2 protein] which results in decreased chemical synthesis of Acetaminophen

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

cytochrome P450, family 24, subfamily a, polypeptide 1

increases expression

Dextran Sulfate results in increased expression of CYP24A1 protein

NCBI chr 3:159,275,947...159,290,383
Ensembl chr 3:159,275,947...159,290,383

G

cytochrome P450, family 26, subfamily b, polypeptide 1

decreases expression

Dextran Sulfate results in decreased expression of CYP26B1 mRNA

NCBI chr 4:117,041,808...117,058,628
Ensembl chr 4:117,041,808...117,058,628

G

cytochrome P450, family 27, subfamily b, polypeptide 1

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP27B1 mRNA
Dextran Sulfate results in decreased expression of CYP27B1 protein

PMID:29950665 PMID:38588969

NCBI chr 7:62,869,340...62,876,242
Ensembl chr 7:62,871,297...62,876,241

G

cytochrome P450, family 2, subfamily b, polypeptide 1

decreases activity
multiple interactions

Dextran Sulfate results in decreased activity of CYP2B1 protein
[Dextran Sulfate results in decreased activity of CYP2B1 protein] which results in decreased chemical synthesis of hydroxybupropion

NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052

G

cytochrome P450, family 2, subfamily b, polypeptide 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2B13 mRNA

NCBI chr 1:81,594,534...81,608,567
Ensembl chr 1:81,594,555...81,608,566

G

cytochrome P450, family 2, subfamily b, polypeptide 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CYP2B10 mRNA

NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143

G

cytochrome P450, family 2, subfamily c, polypeptide 24

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2C55 mRNA

NCBI chr 1:236,873,967...236,936,238
Ensembl chr 1:236,873,967...236,936,238

G

cytochrome P450, family 2, subfamily C, polypeptide 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2C29 mRNA

NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596

G

cytochrome P450, family 2, subfamily c, polypeptide 66

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2C66 mRNA

NCBI chr 1:237,078,517...237,169,841
Ensembl chr 1:237,078,517...237,169,650

G

cytochrome P450, family 2, subfamily e, polypeptide 1

decreases activity
multiple interactions

Dextran Sulfate results in decreased activity of CYP2E1 protein
[Dextran Sulfate results in decreased activity of CYP2E1 protein] which results in decreased chemical synthesis of 6-hydroxychlorzoxazone

NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023

G

cytochrome P450, family 2, subfamily j, polypeptide 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2J9 mRNA

NCBI chr 5:111,179,981...111,207,490
Ensembl chr 5:111,178,703...111,244,794

G

cytochrome P450, family 2, subfamily r, polypeptide 1

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2R1 mRNA; Cholecalciferol inhibits the reaction [Dextran Sulfate results in decreased expression of CYP2R1 protein]

PMID:29950665 PMID:38588969

NCBI chr 1:168,749,302...168,798,079
Ensembl chr 1:168,751,038...168,797,759

G

cytochrome P450, family 2, subfamily s, polypeptide 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2S1 mRNA

NCBI chr 1:81,309,948...81,325,303
Ensembl chr 1:81,310,451...81,325,303

G

cytochrome P450, family 3, subfamily a, polypeptide 9

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP3A13 mRNA

NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422

G

cytochrome P450, family 4, subfamily b, polypeptide 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP4B1 mRNA

NCBI chr 5:129,139,019...129,176,860
Ensembl chr 5:129,139,038...129,156,348

G

cytochrome P450, family 4, subfamily f, polypeptide 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP4F14 mRNA

NCBI chr 7:12,010,850...12,022,497
Ensembl chr 7:12,010,852...12,022,046

G

cytochrome P450, family 4, subfamily f, polypeptide 39

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CYP4F39 mRNA

NCBI chr 7:11,426,806...11,505,553
Ensembl chr 7:11,433,371...11,536,181

G

cytochrome P450 family 7 subfamily A member 1

decreases expression

Dextran Sulfate results in decreased expression of CYP7A1 mRNA

NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688

G

cytochrome P450 family 7 subfamily B member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CYP7B1 mRNA

NCBI chr 2:100,502,791...100,669,713
Ensembl chr 2:100,502,791...100,669,698

G

dihydrolipoamide branched chain transacylase E2

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of DBT protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of DBT protein]

NCBI chr 2:204,481,744...204,510,612
Ensembl chr 2:204,481,737...204,510,609

G

decorin

multiple interactions
increases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DCN mRNA; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of DCN protein]

PMID:29950665 PMID:32272095

NCBI chr 7:32,281,252...32,321,291
Ensembl chr 7:32,281,252...32,321,270

G

discoidin domain receptor tyrosine kinase 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DDR2 mRNA

NCBI chr13:82,193,623...82,318,229
Ensembl chr13:82,195,463...82,317,363

G

DEPP autophagy regulator 1

increases expression

Dextran Sulfate results in increased expression of DEPP1 mRNA

NCBI chr 4:149,910,794...149,913,013
Ensembl chr 4:149,910,779...149,914,542

G

derlin 3

increases expression

Dextran Sulfate results in increased expression of DERL3 mRNA

NCBI chr20:12,754,490...12,768,454
Ensembl chr20:12,763,543...12,767,027

G

diacylglycerol kinase, beta

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DGKB mRNA

NCBI chr 6:54,640,948...55,397,210
Ensembl chr 6:54,641,614...55,397,043

G

diacylglycerol kinase, iota

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of DGKI mRNA

NCBI chr 4:65,410,878...65,872,733
Ensembl chr 4:65,420,108...65,872,733

G

24-dehydrocholesterol reductase

decreases expression

Dextran Sulfate results in decreased expression of DHCR24 mRNA

NCBI chr 5:121,344,552...121,371,124
Ensembl chr 5:121,344,575...121,371,137

G

dehydrogenase/reductase 9

increases expression

Dextran Sulfate results in increased expression of DHRS9 mRNA

NCBI chr 3:54,147,834...54,170,052
Ensembl chr 3:54,147,803...54,220,241

G

dehydrogenase/reductase X-linked

increases expression

Dextran Sulfate results in increased expression of DHRSX mRNA

NCBI chr12:16,299,768...16,304,553
Ensembl chr12:16,299,808...16,304,552

G

dickkopf WNT signaling pathway inhibitor 2

multiple interactions

[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of DKK2 mRNA; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of DKK2 mRNA]

NCBI chr 2:220,568,338...220,660,225
Ensembl chr 2:220,568,338...220,660,225

G

delta like non-canonical Notch ligand 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DLK1 mRNA

NCBI chr 6:128,410,216...128,417,518
Ensembl chr 6:128,410,316...128,417,522

G

DM1 protein kinase

multiple interactions

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of DMPK mRNA

NCBI chr 1:78,730,255...78,740,585
Ensembl chr 1:78,730,275...78,740,593

G

DMRT-like family A1

decreases expression

Dextran Sulfate results in decreased expression of DMRTA1 mRNA

NCBI chr 5:104,415,893...104,422,433
Ensembl chr 5:104,415,893...104,422,433

G

DM1 locus, WD repeat containing

increases expression

Dextran Sulfate results in increased expression of DMWD mRNA

NCBI chr 1:78,722,436...78,729,224
Ensembl chr 1:78,722,330...78,740,593

G

DnaJ heat shock protein family (Hsp40) member C10

increases expression
multiple interactions

Dextran Sulfate results in increased expression of DNAJC10 protein
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of DNAJC10 protein]

NCBI chr 3:65,232,031...65,272,732
Ensembl chr 3:65,232,697...65,272,719

G

dynamin 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DNM1 mRNA

NCBI chr 3:15,604,782...15,648,654
Ensembl chr 3:15,604,784...15,648,538

G

dynamin 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DNM3 mRNA

NCBI chr13:74,359,043...74,838,135
Ensembl chr13:74,359,213...74,838,108

G

docking protein 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DOK2 mRNA

NCBI chr15:45,826,984...45,841,409
Ensembl chr15:45,827,398...45,841,402

G

dipeptidase 1

increases expression
multiple interactions

Dextran Sulfate results in increased expression of DPEP1 protein
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of DPEP1 protein; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of DPEP1 protein]

PMID:32272095 PMID:35999755

NCBI chr19:51,209,831...51,237,004
Ensembl chr19:51,219,660...51,235,257

G

dipeptidase 2

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of DPEP2 protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DPEP2 mRNA

PMID:29950665 PMID:35999755

NCBI chr19:33,883,557...33,896,487
Ensembl chr19:33,885,478...33,891,954

G

dihydropyrimidine dehydrogenase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of DPYD mRNA

NCBI chr 2:206,609,043...207,474,982
Ensembl chr 2:206,609,122...207,474,982

G

Dr1 associated protein 1

increases expression

Dextran Sulfate results in increased expression of DRAP1 mRNA

NCBI chr 1:202,731,775...202,734,468
Ensembl chr 1:202,731,788...202,734,425

G

dopamine receptor D4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of DRD4 mRNA

NCBI chr 1:196,396,366...196,400,824
Ensembl chr 1:196,396,366...196,399,553

G

dopamine receptor D5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of DRD5 mRNA

NCBI chr14:72,487,950...72,491,050
Ensembl chr14:72,489,347...72,490,774

G

deltex E3 ubiquitin ligase 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DTX1 mRNA

NCBI chr12:35,849,647...35,880,835
Ensembl chr12:35,849,617...35,880,838

G

dual oxidase maturation factor 2

increases expression

Dextran Sulfate results in increased expression of DUOXA2 mRNA

NCBI chr 3:109,245,337...109,249,055
Ensembl chr 3:109,245,476...109,248,968

G

dual specificity phosphatase 1

multiple interactions
increases expression

DUSP1 protein affects the reaction [Butylated Hydroxyanisole affects the reaction [Dextran Sulfate affects the expression of IL6 protein]]; DUSP1 protein affects the reaction [Butylated Hydroxyanisole affects the reaction [Dextran Sulfate affects the expression of TNF protein]]; DUSP1 protein affects the reaction [Butylated Hydroxyanisole inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 protein]]; DUSP1 protein affects the reaction [Resveratrol affects the reaction [Dextran Sulfate affects the expression of IL6 protein]]; DUSP1 protein affects the reaction [Resveratrol affects the reaction [Dextran Sulfate affects the expression of TNF protein]]; DUSP1 protein affects the reaction [Resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 protein]]; DUSP1 protein affects the susceptibility to [Azoxymethane co-treated with Dextran Sulfate]
Dextran Sulfate results in increased expression of DUSP1 mRNA

PMID:30844440 PMID:35093514

NCBI chr10:16,680,478...16,683,275

G

enoyl-CoA delta isomerase 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ECI1 mRNA

NCBI chr10:13,456,715...13,470,061
Ensembl chr10:13,456,563...13,470,061

G

Ecm29 proteasome adaptor and scaffold

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of ECPAS protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of ECPAS protein]

NCBI chr 5:73,601,745...73,714,026
Ensembl chr 5:73,604,533...73,713,860

G

ectodysplasin-A

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EDA mRNA

NCBI chr X:65,078,454...65,480,172
Ensembl chr X:65,078,673...65,480,172

G

ectodysplasin A2 receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EDA2R mRNA

NCBI chr X:62,224,763...62,269,333
Ensembl chr X:62,228,229...62,269,268

G

endothelial differentiation-related factor 1

increases expression

Dextran Sulfate results in increased expression of EDF1 mRNA

NCBI chr 3:8,377,058...8,381,363
Ensembl chr 3:8,366,613...8,381,363

G

endothelin 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EDN1 mRNA

NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885

G

endothelin 2

increases expression
multiple interactions

Dextran Sulfate results in increased expression of EDN2 protein
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of EDN2 mRNA

PMID:16216902 PMID:29950665

NCBI chr 5:133,751,316...133,756,814
Ensembl chr 5:133,751,217...133,756,814

G

endothelin receptor type A

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EDNRA mRNA

NCBI chr19:30,233,540...30,303,727
Ensembl chr19:30,233,571...30,297,049

G

eukaryotic translation elongation factor 1 gamma

decreases expression

Dextran Sulfate results in decreased expression of EEF1G protein

NCBI chr 1:205,860,713...205,871,319
Ensembl chr 1:205,860,698...205,872,382

G

EGF containing fibulin extracellular matrix protein 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EFEMP2 mRNA

NCBI chr 1:202,781,692...202,789,784
Ensembl chr 1:202,781,665...202,789,414

G

EF-hand domain family, member D2

increases expression

Dextran Sulfate results in increased expression of EFHD2 mRNA

NCBI chr 5:154,160,945...154,176,980
Ensembl chr 5:154,160,946...154,176,980

G

ephrin A1

multiple interactions

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in decreased expression of EFNA1 mRNA

NCBI chr 2:174,681,676...174,689,061
Ensembl chr 2:174,681,682...174,690,866

G

egl-9 family hypoxia-inducible factor 2

increases expression

Dextran Sulfate results in increased expression of EGLN2 mRNA

NCBI chr 1:82,451,554...82,459,809
Ensembl chr 1:82,451,555...82,459,751

G

EH-domain containing 1

decreases expression

Dextran Sulfate results in decreased expression of EHD1 protein

NCBI chr 1:203,579,850...203,602,226
Ensembl chr 1:203,579,869...203,602,212

G

EH-domain containing 4

multiple interactions
decreases expression

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of EHD4 protein
Dextran Sulfate results in decreased expression of EHD4 protein

NCBI chr 3:107,058,191...107,121,985
Ensembl chr 3:107,058,958...107,122,002

G

enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of EHHADH mRNA

NCBI chr11:79,241,927...79,275,173
Ensembl chr11:79,241,938...79,275,188

G

euchromatic histone lysine methyltransferase 2

increases expression

Dextran Sulfate results in increased expression of EHMT2 mRNA

NCBI chr20:3,919,623...3,936,751
Ensembl chr20:3,919,624...3,941,547

G

eukaryotic translation initiation factor 2-alpha kinase 2

multiple interactions
increases phosphorylation

EIF2AK2 protein affects the reaction [Dextran Sulfate results in increased activity of CASP3 protein]; EIF2AK2 protein affects the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; EIF2AK2 protein affects the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]; EIF2AK2 protein affects the reaction [Dextran Sulfate results in increased phosphorylation of RELA protein]; GW 506033X inhibits the reaction [Dextran Sulfate results in increased phosphorylation of EIF2AK2 protein]

NCBI chr 6:16,189,000...16,224,972
Ensembl chr 6:16,188,979...16,224,971

G

eukaryotic translation initiation factor 3, subunit A

multiple interactions

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of EIF3A mRNA

NCBI chr 1:259,902,767...259,932,976
Ensembl chr 1:259,902,680...259,932,976

G

eukaryotic translation initiation factor 5A

decreases expression

Dextran Sulfate results in decreased expression of EIF5A protein

NCBI chr10:54,640,104...54,644,845
Ensembl chr10:54,640,024...54,644,656

G

eukaryotic translation initiation factor 5B

increases expression

Dextran Sulfate results in increased expression of EIF5B mRNA

NCBI chr 9:40,222,769...40,277,482
Ensembl chr 9:40,222,898...40,277,482

G

elastase, neutrophil expressed

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ELANE mRNA

NCBI chr 7:9,817,251...9,819,174
Ensembl chr 7:9,817,252...9,819,100

G

engulfment and cell motility 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ELMO2 mRNA

NCBI chr 3:154,023,661...154,061,259
Ensembl chr 3:154,023,661...154,061,185

G

ER membrane protein complex subunit 2

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of EMC2 protein]

NCBI chr 7:74,587,196...74,624,163
Ensembl chr 7:74,587,175...74,625,189

G

epithelial membrane protein 2

decreases expression

Dextran Sulfate results in decreased expression of EMP2 mRNA

NCBI chr10:5,360,073...5,394,734
Ensembl chr10:5,360,073...5,394,733

G

endoglin

decreases expression

Dextran Sulfate results in decreased expression of ENG mRNA

NCBI chr 3:15,934,566...15,972,618
Ensembl chr 3:15,934,518...15,973,230

G

enolase 1

decreases expression

Dextran Sulfate results in decreased expression of ENO1 protein

NCBI chr 5:160,719,951...160,731,337
Ensembl chr 5:160,719,951...160,731,336

G

enolase 3

multiple interactions
decreases expression

[Dextran Sulfate co-treated with bisphenol A] results in increased expression of ENO3 protein; Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of ENO3 protein]

PMID:32272095 PMID:35999755

NCBI chr10:55,370,531...55,375,921
Ensembl chr10:55,366,975...55,375,921

G

glutamyl aminopeptidase

multiple interactions
increases expression

Erianin inhibits the reaction [Dextran Sulfate results in increased expression of ENPEP protein]

NCBI chr 2:217,781,985...217,851,947
Ensembl chr 2:217,782,005...217,851,947

G

ectonucleoside triphosphate diphosphohydrolase 5

multiple interactions

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in decreased expression of ENTPD5 mRNA

NCBI chr 6:104,019,095...104,055,311
Ensembl chr 6:104,019,185...104,055,530

G

E1A binding protein p300

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EP300 mRNA

NCBI chr 7:113,108,476...113,178,529
Ensembl chr 7:113,106,247...113,136,088
Ensembl chr 7:113,106,247...113,136,088

G

epoxide hydrolase 1

decreases expression

Dextran Sulfate results in decreased expression of EPHX1 mRNA

NCBI chr13:92,714,315...92,744,105
Ensembl chr13:92,714,315...92,790,235

G

erb-b2 receptor tyrosine kinase 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ERBB2 mRNA

NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078

G

erb-b2 receptor tyrosine kinase 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ERBB3 mRNA

NCBI chr 7:994,549...1,015,876
Ensembl chr 7:996,225...1,015,525

G

erb-b2 receptor tyrosine kinase 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ERBB4 mRNA

NCBI chr 9:69,523,733...70,596,743
Ensembl chr 9:69,531,481...70,596,595

G

epiregulin

decreases response to substance
increases expression

EREG protein results in decreased susceptibility to Dextran Sulfate
dextran sodium sulfate increases expression of Ereg protein in colonic mucosa

CTD
RGD

PMID:15456865 PMID:20498653

NCBI chr14:17,027,287...17,041,062
Ensembl chr14:17,027,287...17,041,062

G

ERBB receptor feedback inhibitor 1

increases expression

Dextran Sulfate results in increased expression of ERRFI1 mRNA

NCBI chr 5:161,323,981...161,337,289
Ensembl chr 5:161,323,998...161,337,282

G

endothelial cell adhesion molecule

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ESAM mRNA

NCBI chr 8:37,238,228...37,249,217
Ensembl chr 8:37,238,287...37,249,215

G

estrogen receptor 1

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of ESR1 mRNA
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ESR1 mRNA

PMID:29950665 PMID:30270565

NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002

G

estrogen receptor 2

multiple interactions

Dextran Sulfate promotes the reaction [Zearalenone results in increased expression of ESR2 mRNA]

NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919

G

Enah/Vasp-like

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EVL mRNA

NCBI chr 6:127,473,119...127,594,342
Ensembl chr 6:127,474,543...127,594,344

G

EWS RNA-binding protein 1

increases expression

Dextran Sulfate results in increased expression of EWSR1 mRNA

NCBI chr14:79,965,365...79,994,108
Ensembl chr14:79,965,368...79,994,544

G

coagulation factor X

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of F10 mRNA

NCBI chr16:76,468,834...76,488,141
Ensembl chr16:76,468,838...76,488,141

G

coagulation factor XI

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of F11 protein

NCBI chr16:46,987,988...47,009,015
Ensembl chr16:46,986,107...47,008,437

G

coagulation factor XIII A1 chain

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of F13A1 mRNA

NCBI chr17:27,815,723...27,992,494
Ensembl chr17:27,815,702...27,992,700

G

coagulation factor II (thrombin) receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of F2R mRNA

NCBI chr 2:26,869,343...26,885,856
Ensembl chr 2:26,868,404...26,885,870

G

F2R like trypsin receptor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of F2RL1 mRNA

NCBI chr 2:26,772,274...26,785,226
Ensembl chr 2:26,772,278...26,785,226

G

coagulation factor V

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of F5 mRNA

NCBI chr13:76,513,509...76,583,106
Ensembl chr13:76,513,255...76,582,317

G

fatty acid amide hydrolase

multiple interactions

[Serotonin co-treated with Dextran Sulfate] results in decreased expression of FAAH protein

NCBI chr 5:129,479,774...129,499,018
Ensembl chr 5:129,479,824...129,498,677

G

fatty acid binding protein 4

multiple interactions
increases expression

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of FABP4 mRNA; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of FABP4 protein]

PMID:26271895 PMID:32272095

NCBI chr 2:91,580,879...91,585,567
Ensembl chr 2:91,580,885...91,585,578

G

fatty acid binding protein 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FABP6 mRNA

NCBI chr10:28,063,603...28,068,276
Ensembl chr10:28,063,603...28,068,282

G

fatty acid desaturase 1

decreases expression

Dextran Sulfate results in decreased expression of FADS1 mRNA

NCBI chr 1:206,827,724...206,842,734
Ensembl chr 1:206,827,765...206,842,734

G

fatty acid desaturase 2

decreases expression

Dextran Sulfate results in decreased expression of FADS2 mRNA

NCBI chr 1:206,707,384...206,747,333
Ensembl chr 1:206,708,783...206,748,789

G

family with sequence similarity 229, member A

increases expression

Dextran Sulfate results in increased expression of FAM229A mRNA

NCBI chr 5:141,829,716...141,830,705
Ensembl chr 5:141,828,664...141,830,705

G

family with sequence similarity 50, member B

increases expression

Dextran Sulfate results in increased expression of FAM50B mRNA

NCBI chr17:30,174,431...30,193,627
Ensembl chr17:30,174,411...30,193,615

G

family with sequence similarity 98, member B

increases expression

Dextran Sulfate results in increased expression of FAM98B mRNA

NCBI chr 3:104,134,803...104,164,249
Ensembl chr 3:104,134,824...104,163,704

G

FAU ubiquitin like and ribosomal protein S30 fusion

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of FAU protein]

NCBI chr 1:203,350,226...203,351,741
Ensembl chr 1:203,350,189...203,351,742

G

fibulin 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FBLN2 mRNA

NCBI chr 4:123,704,289...123,763,857
Ensembl chr 4:123,704,373...123,763,948

G

fibulin 5

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FBLN5 mRNA
Dextran Sulfate results in decreased expression of FBLN5 mRNA

PMID:29950665 PMID:35093514

NCBI chr 6:120,899,219...120,977,829
Ensembl chr 6:120,899,224...120,977,755

G

fibrillin 1

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FBN1 mRNA; Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of FBN1 protein]

PMID:29950665 PMID:32272095

NCBI chr 3:112,554,257...112,750,835
Ensembl chr 3:112,554,925...112,750,889

G

F-box protein 2

increases expression

Dextran Sulfate results in increased expression of FBXO2 mRNA

NCBI chr 5:158,592,926...158,598,355
Ensembl chr 5:158,592,925...158,598,355

G

Fc epsilon receptor Ig

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FCER1G mRNA

NCBI chr13:83,649,447...83,654,248
Ensembl chr13:83,649,449...83,671,443

G

Fc gamma receptor 1A

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FCGR1 mRNA

NCBI chr 2:183,851,075...183,860,077
Ensembl chr 2:183,851,077...183,859,994

G

Fc gamma receptor 2A

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FCGR3 mRNA

NCBI chr13:83,280,782...83,297,535
Ensembl chr13:83,280,784...83,295,967

G

Fc gamma receptor 2B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FCGR2B mRNA

NCBI chr13:83,191,253...83,207,778
Ensembl chr13:83,193,163...83,207,778

G

Fc gamma receptor 3A

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FCGR4 mRNA

NCBI chr13:83,249,905...83,259,921
Ensembl chr13:83,249,872...83,259,921

G

ferredoxin 1

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of FDX1 protein]

NCBI chr 8:52,268,536...52,287,344
Ensembl chr 8:52,268,536...52,287,414

G

ferredoxin reductase

decreases expression

Dextran Sulfate results in decreased expression of FDXR mRNA

NCBI chr10:100,507,863...100,516,649
Ensembl chr10:100,507,865...100,516,658

G

FERM domain containing kindlin 3

increases expression
decreases expression
multiple interactions

Dextran Sulfate results in increased expression of FERMT3 protein
Dextran Sulfate results in decreased expression of FERMT3 protein
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of FERMT3 protein; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of FERMT3 protein]

PMID:32272095 PMID:35999755

NCBI chr 1:204,189,483...204,207,683
Ensembl chr 1:204,189,484...204,207,587

G

free fatty acid receptor 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FFAR2 mRNA

NCBI chr 1:86,071,855...86,075,049
Ensembl chr 1:86,072,184...86,075,033

G

free fatty acid receptor 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FFAR4 mRNA

NCBI chr 1:235,873,576...235,891,597
Ensembl chr 1:235,873,576...235,891,597

G

fibroblast growth factor 18

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FGF18 mRNA

NCBI chr10:17,706,011...17,737,702
Ensembl chr10:17,706,174...17,736,818

G

fibroblast growth factor 19

multiple interactions

Dextran Sulfate results in increased expression of and results in increased secretion of FGF15 protein

NCBI chr 1:200,056,526...200,060,980
Ensembl chr 1:200,056,644...200,060,287

G

fibroblast growth factor 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FGF2 mRNA

NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221

G

fibroblast growth factor 23

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FGF23 mRNA

NCBI chr 4:159,914,267...159,923,821
Ensembl chr 4:159,914,272...159,923,821

G

fibroblast growth factor 8

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FGF8 mRNA

NCBI chr 1:244,584,477...244,590,578
Ensembl chr 1:244,584,652...244,590,359

G

fibroblast growth factor 9

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FGF9 mRNA

NCBI chr15:32,208,993...32,254,952
Ensembl chr15:32,210,074...32,253,309

G

Fibroblast growth factor receptor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FGFR1 mRNA

NCBI chr16:66,491,930...66,547,161
Ensembl chr16:66,494,042...66,547,350

G

fibroblast growth factor receptor 4

increases expression

Dextran Sulfate results in increased expression of FGFR4 mRNA

NCBI chr17:9,461,541...9,476,268
Ensembl chr17:9,461,547...9,476,242

G

fibrinogen-like 1

increases expression

Dextran Sulfate results in increased expression of FGL1 protein

NCBI chr16:51,120,652...51,150,907
Ensembl chr16:51,120,694...51,151,093

G

four and a half LIM domains 1

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of FHL1 protein

NCBI chr X:134,555,399...134,614,930
Ensembl chr X:134,555,479...134,614,928

G

four and a half LIM domains 2

decreases expression

Dextran Sulfate results in decreased expression of FHL2 mRNA

NCBI chr 9:45,388,979...45,462,421
Ensembl chr 9:45,388,981...45,431,192

G

four and a half LIM domains 3

increases expression
multiple interactions

Dextran Sulfate results in increased expression of FHL3 protein
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of FHL3 protein]

NCBI chr 5:136,953,947...136,961,317
Ensembl chr 5:136,950,411...136,961,317

G

filamin A

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of FLNA protein

NCBI chr X:152,007,758...152,034,266
Ensembl chr X:152,007,758...152,031,052

G

flotillin 2

increases expression
multiple interactions

Dextran Sulfate results in increased expression of FLOT2 protein
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of FLOT2 protein]

NCBI chr10:62,926,047...62,947,759
Ensembl chr10:62,920,665...62,947,756

G

Fms related receptor tyrosine kinase 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FLT1 mRNA

NCBI chr12:7,296,899...7,468,626
Ensembl chr12:7,297,292...7,468,626

G

Fms related receptor tyrosine kinase 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FLT4 mRNA

NCBI chr10:33,913,725...33,954,770
Ensembl chr10:33,913,608...33,954,770

G

flavin containing dimethylaniline monoxygenase 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FMO1 mRNA

NCBI chr13:75,182,184...75,214,439
Ensembl chr13:75,182,176...75,214,647

G

fibromodulin

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FMOD mRNA

NCBI chr13:45,493,517...45,504,134
Ensembl chr13:45,493,517...45,504,133

G

fibronectin 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FN1 mRNA

NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions
increases expression

Dextran Sulfate promotes the reaction [Capsaicin results in increased expression of FOS protein]; GRK6 mutant form promotes the reaction [Dextran Sulfate promotes the reaction [Capsaicin results in increased expression of FOS protein]]
Dextran Sulfate results in increased expression of FOS mRNA

PMID:18687398 PMID:35093514

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

FOS like 1, AP-1 transcription factor subunit

increases expression

Dextran Sulfate results in increased expression of FOSL1 protein

NCBI chr 1:202,754,549...202,763,057
Ensembl chr 1:202,754,529...202,764,930

G

forkhead box A2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FOXA2 mRNA

NCBI chr 3:135,470,123...135,474,326
Ensembl chr 3:135,470,131...135,474,326

G

forkhead box A3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FOXA3 mRNA

NCBI chr 1:78,662,067...78,672,321
Ensembl chr 1:78,662,431...78,672,155

G

forkhead box O1

increases expression

Dextran Sulfate results in increased expression of FOXO1 mRNA; Dextran Sulfate results in increased expression of FOXO1 protein

NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790

G

forkhead box O3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FOXO3 mRNA

NCBI chr20:45,669,708...45,764,606
Ensembl chr20:45,672,995...45,764,561

G

forkhead box O4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FOXO4 mRNA

NCBI chr X:66,385,241...66,392,115
Ensembl chr X:66,385,558...66,392,115

G

forkhead box P3

increases methylation
increases expression
multiple interactions

Dextran Sulfate results in increased methylation of FOXP3 gene
Dextran Sulfate results in increased expression of FOXP3 mRNA
kappa-casein glycomacropeptide inhibits the reaction [Dextran Sulfate results in increased expression of FOXP3 mRNA]
Chlorpyrifos inhibits the reaction [Dextran Sulfate results in increased expression of FOXP3 mRNA]; Tetrachlorodibenzodioxin inhibits the reaction [Dextran Sulfate results in increased methylation of FOXP3 gene]

PMID:20881082 PMID:21858153 PMID:31807802 PMID:34998820

NCBI chr X:14,908,494...14,924,994
Ensembl chr X:14,908,494...14,923,838

G

fucose-1-phosphate guanylyltransferase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FPGT mRNA

NCBI chr 2:244,099,031...244,119,967
Ensembl chr 2:244,099,076...244,119,899

G

formyl peptide receptor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FPR1 mRNA

NCBI chr 1:58,745,019...58,756,776
Ensembl chr 1:58,747,246...58,756,559

G

formyl peptide receptor 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FPR2 mRNA

NCBI chr 1:58,776,592...58,785,227
Ensembl chr 1:58,776,752...58,786,019

G

formyl peptide receptor 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FPR3 mRNA

NCBI chr 1:58,884,427...58,893,472
Ensembl chr 1:58,845,118...58,893,467

G

FRAT regulator of WNT signaling pathway 2

increases expression

Dextran Sulfate results in increased expression of FRAT2 mRNA

NCBI chr 1:240,654,120...240,656,449
Ensembl chr 1:240,654,137...240,656,517

G

follicle stimulating hormone subunit beta

multiple interactions
decreases expression

gingerol inhibits the reaction [Dextran Sulfate results in decreased expression of FSHB protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in decreased expression of FSHB protein]

NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370

G

follicle stimulating hormone receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FSHR mRNA

NCBI chr 6:5,198,825...5,406,785
Ensembl chr 6:5,198,825...5,406,785

G

follistatin

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FST mRNA

NCBI chr 2:46,123,260...46,130,584
Ensembl chr 2:46,123,439...46,130,571

G

follistatin like 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FSTL3 mRNA

NCBI chr 7:9,923,574...9,929,223
Ensembl chr 7:9,923,576...9,939,639

G

Fus RNA binding protein

increases expression

Dextran Sulfate results in increased expression of FUS mRNA

NCBI chr 1:182,576,479...182,590,417
Ensembl chr 1:182,576,545...182,590,414

G

FXYD domain-containing ion transport regulator 1

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FXYD1 mRNA
Dextran Sulfate results in decreased expression of FXYD1 mRNA

PMID:29950665 PMID:35093514

NCBI chr 1:86,287,163...86,291,478
Ensembl chr 1:86,287,165...86,291,278

G

FXYD domain-containing ion transport regulator 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FXYD3 mRNA

NCBI chr 1:86,305,531...86,312,455

G

FXYD domain-containing ion transport regulator 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FXYD4 mRNA

NCBI chr 4:151,109,779...151,113,659
Ensembl chr 4:151,109,779...151,113,637

G

FYN proto-oncogene, Src family tyrosine kinase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FYN mRNA

NCBI chr20:42,767,733...42,960,903
Ensembl chr20:42,766,369...42,959,911

G

frizzled class receptor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FZD1 mRNA

NCBI chr 4:29,310,303...29,314,701
Ensembl chr 4:29,310,091...29,312,643
Ensembl chr 4:29,310,091...29,312,643

G

frizzled class receptor 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FZD4 mRNA

NCBI chr 1:143,279,934...143,288,799
Ensembl chr 1:143,280,065...143,285,724

G

frizzled class receptor 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FZD5 mRNA

NCBI chr 9:66,113,096...66,120,276
Ensembl chr 9:66,113,112...66,121,457

G

frizzled class receptor 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FZD6 mRNA

NCBI chr 7:70,055,012...70,086,781
Ensembl chr 7:70,055,068...70,086,776

G

frizzled class receptor 7

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FZD7 mRNA

NCBI chr 9:60,931,433...60,934,252
Ensembl chr 9:60,930,875...60,935,781

G

frizzled class receptor 8

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FZD8 mRNA

NCBI chr17:57,312,924...57,320,551
Ensembl chr17:57,314,450...57,320,650

G

glucose-6-phosphatase catalytic subunit 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of G6PC1 mRNA

NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804

G

gamma-aminobutyric acid type B receptor subunit 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GABBR1 mRNA

NCBI chr20:1,464,534...1,494,114
Ensembl chr20:1,464,534...1,493,994

G

gamma-aminobutyric acid type A receptor subunit alpha 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GABRA2 mRNA

NCBI chr14:37,097,251...37,230,030
Ensembl chr14:37,097,279...37,228,944

G

gamma-aminobutyric acid type A receptor subunit alpha 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GABRA5 mRNA

NCBI chr 1:108,268,728...108,381,670
Ensembl chr 1:108,268,776...108,380,917

G

gamma-aminobutyric acid type A receptor subunit beta 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GABRB2 mRNA

NCBI chr10:26,936,592...27,156,141
Ensembl chr10:26,936,551...27,151,251

G

gamma-aminobutyric acid type A receptor subunit delta

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GABRD mRNA

NCBI chr 5:165,958,508...165,970,407
Ensembl chr 5:165,958,484...165,970,411

G

glutamate decarboxylase 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GAD1 mRNA

NCBI chr 3:55,369,704...55,410,335
Ensembl chr 3:55,369,704...55,410,333

G

UDP-galactose-4-epimerase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALE mRNA

NCBI chr 5:148,193,886...148,198,392
Ensembl chr 5:148,194,791...148,198,388

G

galactokinase 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALK2 mRNA

NCBI chr 3:113,110,057...113,243,014
Ensembl chr 3:113,110,030...113,233,306

G

galactose mutarotase

increases expression

Dextran Sulfate results in increased expression of GALM mRNA

NCBI chr 6:14,837,540...14,889,484
Ensembl chr 6:14,837,548...14,889,310

G

polypeptide N-acetylgalactosaminyltransferase 10

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALNT10 mRNA

NCBI chr10:41,821,216...41,967,618
Ensembl chr10:41,820,158...41,967,013

G

polypeptide N-acetylgalactosaminyltransferase 12

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALNT12 mRNA

NCBI chr 5:61,384,575...61,413,346
Ensembl chr 5:61,384,571...61,413,354

G

polypeptide N-acetylgalactosaminyltransferase 15

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GALNT15 mRNA

NCBI chr16:7,227,232...7,267,002
Ensembl chr16:7,227,271...7,267,014

G

polypeptide N-acetylgalactosaminyltransferase 16

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GALNT16 mRNA

NCBI chr 6:100,168,943...100,250,718
Ensembl chr 6:100,170,306...100,250,705

G

polypeptide N-acetylgalactosaminyltransferase 18

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GALNT18 mRNA

NCBI chr 1:165,593,180...165,904,268
Ensembl chr 1:165,593,187...165,904,268

G

polypeptide N-acetylgalactosaminyltransferase 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GALNT2 mRNA

NCBI chr19:52,213,226...52,324,816
Ensembl chr19:52,213,351...52,324,813

G

polypeptide N-acetylgalactosaminyltransferase 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALNT4 mRNA

NCBI chr 7:33,925,229...33,927,770

G

polypeptide N-acetylgalactosaminyltransferase 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALNT5 mRNA

NCBI chr 3:42,573,622...42,619,881
Ensembl chr 3:42,573,622...42,619,881

G

polypeptide N-acetylgalactosaminyltransferase 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALNT6 mRNA

NCBI chr 7:131,789,836...131,828,077
Ensembl chr 7:131,789,839...131,819,661

G

polypeptide N-acetylgalactosaminyltransferase 7

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALNT7 mRNA

NCBI chr16:32,578,643...32,703,189
Ensembl chr16:32,578,690...32,702,690

G

polypeptide N-acetylgalactosaminyltransferase-like 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALNTL6 mRNA

NCBI chr16:31,192,880...32,443,979
Ensembl chr16:31,186,462...32,441,960

G

GAR1 ribonucleoprotein

increases expression

Dextran Sulfate results in increased expression of GAR1 mRNA

NCBI chr 2:218,375,231...218,382,509
Ensembl chr 2:218,375,353...218,382,524

G

growth arrest specific 8

increases expression

Dextran Sulfate results in increased expression of GAS8 mRNA

NCBI chr19:51,552,770...51,572,323
Ensembl chr19:51,552,816...51,572,305

G

gastrin

decreases response to substance
multiple interactions

GAST protein modified form results in decreased susceptibility to Dextran Sulfate
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GAST mRNA

PMID:16618411 PMID:29950665

NCBI chr10:85,264,832...85,269,393
Ensembl chr10:85,264,832...85,267,496

G

GATA binding protein 2

multiple interactions

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of GATA2 mRNA

NCBI chr 4:120,654,205...120,667,763
Ensembl chr 4:120,658,986...120,667,761

G

guanylate binding protein family member 6

increases expression
multiple interactions

Dextran Sulfate results in increased expression of GBP9 protein
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of GBP9 protein]

NCBI chr14:4,730,286...4,756,508
Ensembl chr14:4,730,453...4,839,062
Ensembl chr14:4,730,453...4,839,062

G

glutamate-cysteine ligase, catalytic subunit

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GCLC mRNA

NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544

G

glutamate cysteine ligase, modifier subunit

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GCLM mRNA

NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535

G

glucosaminyl (N-acetyl) transferase 3, mucin type

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GCNT3 mRNA

NCBI chr 8:70,689,173...70,696,476
Ensembl chr 8:70,686,844...70,699,562

G

GDP dissociation inhibitor 1

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of GDI1 protein

NCBI chr X:152,087,611...152,094,274
Ensembl chr X:152,087,444...152,094,272

G

glutamine fructose-6-phosphate transaminase 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GFPT1 mRNA

NCBI chr 4:119,496,691...119,546,472
Ensembl chr 4:119,496,714...119,546,471

G

glutamine-fructose-6-phosphate transaminase 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GFPT2 mRNA

NCBI chr10:34,115,005...34,161,329
Ensembl chr10:34,115,052...34,161,329

G

GDP-L-fucose synthase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GFUS mRNA

NCBI chr 7:107,612,087...107,617,005
Ensembl chr 7:107,612,094...107,616,948

G

golgi-associated, olfactory signaling regulator

increases expression

Dextran Sulfate results in increased expression of GFY mRNA

NCBI chr 1:95,661,621...95,665,300
Ensembl chr 1:95,661,773...95,665,893

G

gamma-glutamyl cyclotransferase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GGCT mRNA

NCBI chr 4:84,122,921...84,129,327
Ensembl chr 4:84,123,118...84,129,277

G

gametogenetin binding protein 1

increases expression

Dextran Sulfate results in increased expression of GGNBP1 mRNA

NCBI chr20:5,109,849...5,116,185
Ensembl chr20:5,099,311...5,116,183

G

growth hormone 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GH mRNA

NCBI chr10:91,228,102...91,230,079
Ensembl chr10:91,228,103...91,230,078

G

ghrelin and obestatin prepropeptide

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GHRL mRNA

NCBI chr 4:146,865,712...146,869,621
Ensembl chr 4:146,865,712...146,869,621

G

galactosidase, beta 1

increases expression
multiple interactions

Dextran Sulfate results in increased expression of GLB1 protein
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of GLB1 protein]

NCBI chr 8:114,085,508...114,158,127
Ensembl chr 8:114,085,508...114,158,127

G

galactosidase, beta 1-like 2

decreases expression

Dextran Sulfate results in decreased expression of GLB1L2 mRNA

NCBI chr 8:25,115,462...25,166,843
Ensembl chr 8:25,115,462...25,166,783

G

GLI family zinc finger 1

decreases expression

Dextran Sulfate results in decreased expression of GLI1 mRNA

NCBI chr 7:63,156,926...63,169,579
Ensembl chr 7:63,156,926...63,169,251

G

GLI family zinc finger 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GLI3 mRNA

NCBI chr17:49,438,567...49,709,712
Ensembl chr17:49,438,567...49,709,712

G

glucagon-like peptide 1 receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GLP1R mRNA

NCBI chr20:8,972,004...9,010,241
Ensembl chr20:8,972,004...9,010,241

G

glutaminase

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of GLS protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of GLS protein]

NCBI chr 9:49,344,616...49,416,900
Ensembl chr 9:49,344,781...49,416,900

G

GDP-mannose 4, 6-dehydratase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GMDS mRNA

NCBI chr17:32,095,315...32,621,975
Ensembl chr17:32,095,386...32,621,961

G

G protein subunit alpha 11

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GNA11 mRNA

NCBI chr 7:8,163,520...8,177,863
Ensembl chr 7:8,162,750...8,179,812

G

G protein subunit alpha 12

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GNA12 mRNA

NCBI chr12:13,805,580...13,886,255
Ensembl chr12:13,805,698...13,886,255

G

G protein subunit alpha 14

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GNA14 mRNA

NCBI chr 1:213,714,993...213,900,083
Ensembl chr 1:213,716,020...213,897,423

G

G protein subunit alpha 15

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GNA15 mRNA

NCBI chr 7:8,184,632...8,205,508
Ensembl chr 7:8,184,861...8,205,508

G

G protein subunit alpha z

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GNAZ mRNA

NCBI chr20:13,643,473...13,694,240
Ensembl chr20:13,644,640...13,669,907

G

G protein subunit beta 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GNB3 mRNA

NCBI chr 4:157,639,468...157,645,171
Ensembl chr 4:157,639,469...157,645,173

G

glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GNE mRNA

NCBI chr 5:58,267,189...58,307,396
Ensembl chr 5:58,267,210...58,307,499

G

G protein subunit gamma 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GNG4 mRNA

NCBI chr17:86,448,708...86,497,560
Ensembl chr17:86,449,022...86,495,254

G

G protein subunit gamma 7

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GNG7 mRNA

NCBI chr 7:8,697,458...8,761,239
Ensembl chr 7:8,697,521...8,761,240

G

G protein subunit gamma 8

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GNG8 mRNA

NCBI chr 1:77,564,512...77,568,371
Ensembl chr 1:77,564,515...77,568,371

G

G protein subunit gamma transducin 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GNGT2 mRNA

NCBI chr10:80,776,003...80,784,235

G

G protein nucleolar 1

increases expression

Dextran Sulfate results in increased expression of GNL1 mRNA

NCBI chr20:2,783,130...2,792,115
Ensembl chr20:2,778,985...2,792,115

G

glucosamine-phosphate N-acetyltransferase 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GNPNAT1 mRNA

NCBI chr15:18,596,180...18,608,854
Ensembl chr15:18,596,442...18,608,739

G

glutamic-oxaloacetic transaminase 1

multiple interactions
increases activity

Fatty Acids, Omega-3 inhibits the reaction [Dextran Sulfate results in increased activity of GOT1 protein]

NCBI chr 1:242,357,293...242,381,535
Ensembl chr 1:242,357,306...242,380,633

G

glycoprotein Ib platelet subunit beta

increases expression

Dextran Sulfate results in increased expression of GP1BB mRNA

NCBI chr11:82,378,216...82,379,393
Ensembl chr11:82,378,199...82,379,392

G

glycoprotein VI

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of GP6 protein

NCBI chr 1:69,429,232...69,492,709
Ensembl chr 1:69,465,789...69,491,326

G

G protein-coupled bile acid receptor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPBAR1 mRNA

NCBI chr 9:75,860,758...75,863,260
Ensembl chr 9:75,860,677...75,863,168

G

glypican 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPC4 mRNA

NCBI chr X:131,644,711...131,755,349
Ensembl chr X:131,644,704...131,755,284

G

glucose-6-phosphate isomerase

decreases expression

Dextran Sulfate results in decreased expression of GPI protein

NCBI chr 1:86,828,211...86,856,077
Ensembl chr 1:86,828,216...86,856,086

G

glycoprotein nmb

increases expression

Dextran Sulfate results in increased expression of GPNMB mRNA

NCBI chr 4:78,010,247...78,031,491
Ensembl chr 4:78,010,197...78,049,367

G

G protein-coupled receptor 119

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of GPR119 mRNA

NCBI chr X:127,852,145...127,858,198
Ensembl chr X:127,852,145...127,858,198

G

G protein-coupled receptor 137B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPR137B mRNA

NCBI chr17:86,003,635...86,041,841
Ensembl chr17:85,966,921...86,041,835

G

G protein-coupled receptor 149

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPR149 mRNA

NCBI chr 2:146,909,710...146,981,924
Ensembl chr 2:146,909,713...146,981,167

G

G protein-coupled receptor 15

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GPR15 mRNA

NCBI chr11:41,898,300...41,899,646
Ensembl chr11:41,898,356...41,900,441

G

G protein-coupled receptor 152

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GPR152 mRNA

NCBI chr 1:201,435,878...201,438,373
Ensembl chr 1:201,435,884...201,437,443

G

G protein-coupled receptor 17

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GPR17 mRNA

NCBI chr18:23,576,232...23,583,153
Ensembl chr18:23,577,242...23,582,966

G

G protein-coupled receptor 176

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPR176 mRNA

NCBI chr 3:105,236,794...105,337,664
Ensembl chr 3:105,236,795...105,337,226

G

G protein-coupled receptor 20

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPR20 mRNA

NCBI chr 7:105,601,761...105,611,959
Ensembl chr 7:105,602,368...105,603,430

G

G protein-coupled receptor 27

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GPR27 mRNA

NCBI chr 4:132,328,364...132,329,497
Ensembl chr 4:132,328,364...132,329,497

G

G protein-coupled receptor 37-like 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GPR37L1 mRNA

NCBI chr13:46,598,574...46,605,421
Ensembl chr13:46,598,578...46,605,421

G

G protein-coupled receptor 39

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GPR39 mRNA

NCBI chr13:37,115,258...37,327,312
Ensembl chr13:37,115,102...37,328,267

G

G protein-coupled receptor 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPR4 mRNA

NCBI chr 1:78,865,376...78,877,126
Ensembl chr 1:78,865,409...78,876,599

G

G protein-coupled receptor 50

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GPR50 mRNA

NCBI chr X:149,368,900...149,373,486
Ensembl chr X:149,368,900...149,373,486

G

G protein-coupled receptor 68

multiple interactions

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GPR68 mRNA

NCBI chr 6:120,135,620...120,166,089
Ensembl chr 6:120,135,436...120,166,089

G

G protein-coupled receptor 83

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPR83 mRNA

NCBI chr 8:11,693,540...11,704,028
Ensembl chr 8:11,693,540...11,704,028

G

G protein-coupled receptor 85

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPR85 mRNA

NCBI chr 4:42,100,138...42,109,584
Ensembl chr 4:42,102,941...42,109,566

G

G-protein coupled receptor 88

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPR88 mRNA

NCBI chr 2:204,191,443...204,199,576
Ensembl chr 2:204,191,427...204,199,733

G

G protein-coupled receptor, class C, group 5, member B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPRC5B mRNA

NCBI chr 1:173,316,904...173,340,933
Ensembl chr 1:173,316,907...173,340,932

G

G protein-coupled receptor, class C, group 5, member D

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPRC5D mRNA

NCBI chr 4:167,943,523...167,955,616
Ensembl chr 4:167,943,523...167,955,616

G

glutamic--pyruvic transaminase

decreases activity

Dextran Sulfate results in decreased activity of GPT protein

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

glutamic--pyruvic transaminase 2

decreases expression

Dextran Sulfate results in decreased expression of GPT2 mRNA

NCBI chr19:21,526,800...21,561,314
Ensembl chr19:21,517,621...21,560,610

G

glutathione peroxidase 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPX3 mRNA

NCBI chr10:39,028,624...39,036,695
Ensembl chr10:39,028,570...39,037,035

G

glutathione peroxidase 4

decreases expression
decreases activity
multiple interactions

Dextran Sulfate results in decreased expression of GPX4 mRNA; Dextran Sulfate results in decreased expression of GPX4 protein
Dextran Sulfate results in decreased activity of GPX4 protein
gingerenone A inhibits the reaction [Dextran Sulfate results in decreased expression of GPX4 mRNA]; gingerenone A inhibits the reaction [Dextran Sulfate results in decreased expression of GPX4 protein]

NCBI chr 7:9,650,186...9,652,982
Ensembl chr 7:9,650,185...9,652,982

G

glutathione peroxidase 6

decreases expression

Dextran Sulfate results in decreased expression of GPX6 mRNA

NCBI chr17:43,408,472...43,416,091
Ensembl chr17:43,408,472...43,416,091

G

glutathione peroxidase 7

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPX7 mRNA

NCBI chr 5:123,145,151...123,153,141
Ensembl chr 5:123,144,331...123,153,004

G

glutathione peroxidase 8

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPX8 mRNA

NCBI chr 2:44,676,448...44,680,042
Ensembl chr 2:44,676,454...44,680,195

G

growth factor receptor bound protein 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GRB2 mRNA

NCBI chr10:100,881,404...100,949,193
Ensembl chr10:100,869,718...100,949,309

G

growth factor receptor bound protein 7

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GRB7 mRNA

NCBI chr10:83,443,387...83,453,057
Ensembl chr10:83,444,004...83,453,052

G

gremlin 1, DAN family BMP antagonist

multiple interactions
increases expression

Erianin inhibits the reaction [Dextran Sulfate results in increased expression of GREM1 protein]

NCBI chr 3:100,512,317...100,524,001
Ensembl chr 3:100,512,313...100,524,082

G

glutamate ionotropic receptor kainate type subunit 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GRIK4 mRNA

NCBI chr 8:42,903,043...43,331,990
Ensembl chr 8:42,905,056...43,193,751

G

glutamate ionotropic receptor NMDA type subunit 2B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GRIN2B mRNA

NCBI chr 4:168,580,824...169,044,110
Ensembl chr 4:168,599,546...169,042,279

G

glutamate ionotropic receptor NMDA type subunit 2D

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GRIN2D mRNA

NCBI chr 1:96,306,871...96,346,994
Ensembl chr 1:96,308,365...96,344,793

G

G protein-coupled receptor kinase 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GRK3 mRNA

NCBI chr12:43,624,778...43,735,375
Ensembl chr12:43,624,897...43,731,262

G

G protein-coupled receptor kinase 6

multiple interactions
decreases response to substance

GRK6 mutant form promotes the reaction [Dextran Sulfate promotes the reaction [Capsaicin results in increased expression of FOS protein]]
GRK6 results in decreased susceptibility to Dextran Sulfate

NCBI chr17:9,177,018...9,192,813
Ensembl chr17:9,177,019...9,192,644

G

glutamate metabotropic receptor 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GRM4 mRNA

NCBI chr20:5,484,172...5,572,821
Ensembl chr20:5,481,124...5,572,821

G

gastrin releasing peptide receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GRPR mRNA

NCBI chr X:30,998,425...31,038,442
Ensembl chr X:30,998,416...31,038,442

G

gasdermin D

multiple interactions
increases cleavage

hydroxysafflor yellow A inhibits the reaction [Dextran Sulfate results in increased cleavage of GSDMD protein]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased cleavage of GSDMD protein]

NCBI chr 7:107,542,489...107,547,051
Ensembl chr 7:107,542,083...107,547,055

G

gelsolin

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GSN mRNA

NCBI chr 3:18,585,166...18,638,404
Ensembl chr 3:18,585,172...18,638,402

G

glutathione-disulfide reductase

decreases activity
multiple interactions

Dextran Sulfate results in decreased activity of GSR protein
Fatty Acids, Omega-3 inhibits the reaction [Dextran Sulfate results in decreased activity of GSR protein]

NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661

G

glutathione synthetase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GSS mRNA

NCBI chr 3:144,047,849...144,078,197
Ensembl chr 3:144,047,850...144,078,198

G

glutathione S-transferase kappa 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GSTK1 mRNA

NCBI chr 4:71,118,979...71,123,298
Ensembl chr 4:71,118,896...71,123,292

G

glutathione S-transferase mu 1

decreases expression

Dextran Sulfate results in decreased expression of GSTM1 mRNA

NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411

G

glutathione S-transferase mu 2

decreases expression

Dextran Sulfate results in decreased expression of GSTM2 mRNA